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The use of combination Antiretroviral Therapy (cART) has grown since its first introduction 
into the South African public sector. cART has significantly reduced the mortality rate caused 
by human immunodeficiency virus (HIV) in both high- and low-to-middle-income countries. 
The development of drug resistance has challenged the outcome of cART. This has led to the 
introduction of Integrase (IN) strand transfer inhibitors (InSTIs) as part of the first-line cART 
regimen. Due to their superior efficacy and high genetic barrier, this class of drugs was 
previously reserved as salvage therapy. The World Health Organization (WHO) supports 
InSTIs as first-line regimen non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
particularly in regions where pre-treatment drug resistance to NNRTIs reaches 10%. Therefore, 
this study aimed to (i) to investigate the prevalence of InSTI mutations in treatment-naïve and 
treatment-experienced PLHIV using genotypic assays, which included Sanger sequencing, 
next-generation sequencing (NGS) and molecular modelling; (ii) analysed Long Terminal 
Repeats (LTR) to identify transcription factor binding sites.  
Chapter 2: Ninety-one (n = 91) treatment-naïve patients were obtained before the start of 
antiretroviral treatment in South Africa. Furthermore, we included 314 South African patient 
sequences obtained from the Los Alamos National Library database (www.lanl.gov). The IN 
gene ~ 900 base pairs [bps] was amplified and sequenced using conventional DNA Sanger 
sequencing. Homology structure was generated using the cryoEM structure of HIV-1B IN 
intasome (PDB file 5U1C) using ‘Prime’ of Schrodinger Suit. Chapter 3: Ninety-six (n = 96) 
treatment-experienced patients receiving boosted protease inhibitors (bPIs) as part of their 
cART treatment regimen were obtained for further analyses. We performed conventional DNA 
Sanger sequencing to analyse the complete pol gene (~3011bps) and sequences were analysed 
using the Stanford HIV drug resistance database to assess genotypic resistance associated 
mutations (RAMs). Chapter 4: Fifty-six (n = 56) treatment-experienced patients receiving 
boosted protease inhibitors (bPIs) as part of their cART treatment regimen were obtained. We 
performed a high-throughput (HT) sequence analyses on the complete pol gene using Illumina 
HiSeq2500, followed by bioinformatics analysis to quantify the RAMs according to the 
Stanford HIV drug resistance database. Chapter 5 and 6: We performed in-silico analyses on 
diverse HIV-1 subtypes based on 8114 sequences. These included treatment naïve and 
downloaded sequences from the HIV Los Alamos National Library Database (www.lanl.gov). 




generated using cryoEM structure of the HIV-1B IN intasome. Chapter 7: Fifty-six (n = 56) 
treatment-experienced patients receiving boosted protease inhibitors (bPIs) as part of their 
cART treatment regimen were obtained. We performed Sanger sequencing to analyse the LTR 
gene (~ 474 bps) followed by bioinformatics analyses to identify transcription factor binding 
sites.  
The data indicates that in South Africa, the prevalence of RAMs against InSTIs is low and 
InSTIs can be used as a potential viable salvage therapy option and/or first-line regimen. 
Molecular modelling was done for IN structural analyses, which revealed how naturally 
occurring polymorphisms might affect structural stabilities, viral DNA binding and drug-
binding propensity. This study represents a true baseline InSTI resistance rate as the treatment-
naïve patients were obtained before the cART introduction. We propose  GRT for people living 
with HIV (PLHIV) before treatment initiation and we recommend continued InSTIs drug 






Kombinasie- antiretrovirale terapie (cART) het heelwat toegeneem sedert dit die eerste keer in 
die Suid-Afrikaanse openbare sektor bekend gestel is. cART het ’n aansienlike verlaging in die 
sterftesyfer in sowel hoë- as lae-/middelinkomstelande teweeggebring. Die ontwikkeling van 
middelweerstandigheid en oorgeërfde middelweerstandige mutasies hou egter ’n uitdaging vir 
die uitkoms van cART in. Daarom is integrasestringoordraginhibitors (InSTI’s) by die 
eerstelinie-ART-regime ingesluit. Hierdie klas middels is voorheen uitsluitlik as 
reddingsterapie gebruik weens hulle uitmuntende doeltreffendheid en hoë genetiese skans. Die 
Wêreldgesondheidsorganisasie ondersteun InSTI’s as eerstelinieregime, veral in streke waar 
voorbehandelingsweerstand teen nie-nukleosied-omgekeerdetranskriptase-inhibitors 10% 
bereik. 
Vir hierdie studie is ’n deursneeondersoek uitgevoer wat bestaan het uit die genotipiese en 
molekulêre modellering van InSTI’s vir die volgende: 
Behandelingsnaïewe pasiënte voor bekendstelling van die Suid-Afrikaanse nasionale 
menslike-immuniteitsgebreksvirus-(MIV-)behandelingsprogram en die beskikbaarheid van 
InSTI’s in Suid-Afrika. 
Behandelingservare pasiënte wat tweedelinie-ART in die Suid-Afrikaanse nasionale 
behandelingsprogram ontvang. 
Hoëdeursetreeksvorming (HTS) by behandelingservare pasiënte wat tweedelinie-ART in die 
Suid-Afrikaanse nasionale behandelingsprogram ontvang. 
Die strukturele implikasie van genotipiese variasies in MIV-1-integrase (IN) by sowel 
behandelingservare as behandelingsnaïewe pasiënte. 
Vir behandelingsnaïewe pasiënte is genetiese ontledings van 91 plasmamonsters sowel as 314 
pasiënte se databasisafkomstige reekse gedoen. Genotipiese weerstandigheidstoetsing (GRT) 
het op die Q148-roete afgekom, wat tweedegenerasie-dolutegravir uit die databasisafkomstige 
reekse kan beïnvloed. Nietemin is geen weerstandigheidsverwante mutasies (RAM’e) 
opgemerk in monsters wat voor die bekendstelling van die nasionale MIV-
behandelingsprogram bekom is nie. 
Vir behandelingservare pasiënte is die genotipiese Sanger-reeksvormingsessai gebruik om 




teen raltegravir (RAL) en elvitegravir (EVG). HTS is gebruik om geringe (<20% van die 
populasie) en erge variante binne die MIV quasispecies (>20% van die populasie) by 
behandelingservare pasiënte te kwantifiseer. HTS het InSTI-RAM’e soos Y143R, S147G en 
E138R aan die lig gebring, wat weerstand bied teen RAL en EVG. Molekulêre modellering is 
vir IN- strukturele ontledings uitgevoer, wat getoon het hoe natuurlike polimorfismes 
strukturele stabiliteit, virale DNS-binding en middelbindingsgeneigdheid kan beïnvloed. 
Die studiedata dui op ’n lae voorkoms van RAM’e teen InSTI’s in Suid-Afrika. InSTI’s kan as 
’n potensieel lewensvatbare reddingsterapie en/of eerstelinieregime gebruik word. Die studie 
bied ’n ware basislynaanduiding van InSTI-weerstandigheid omdat die behandelingsnaïewe 
pasiënte voor die bekendstelling van cART gewerf is. Nogtans beveel die navorsers GRT aan 
vir MIV-geïnfekteerde persone voor die aanvang van behandeling, en word die gebruik van 
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Chapter 1 Background and literature review 
1.1. Background 
Acquired immunodeficiency syndrome (AIDS) is one of the most common causes of morbidity and 
mortality in Africa. The human immunodeficiency virus (HIV), which is a retrovirus, is the causative 
agent of AIDS. There are two different types of HIV that infect humans: HIV-1 and HIV-2.1,2 
Phylogenetically, HIV-1 is classified into four main groups: groups M (major), O (outlier), N (non-
M, non-O) and P (putative). Group M is responsible for the majority of HIV/AIDS infections, 
representing > 90% of all HIV infections and driving the global epidemic.1,2 HIV-1 group M has been 
further classified into nine different subtypes (A-D, F, G, H, J and K), at least 98 circulating 
recombinant forms (CRFs) and numerous unique recombinant forms (URFs) (Los Alamos HIV 
database, www.lanl.gov accessed on 17 May 2019). HIV-2 is also phylogenetically categorised into 
groups A-H, but is restricted to Central and West Africa and is thought to be much less severe than 
HIV-1.1,2 
More than 30 years since the first identification of HIV in 1981, due to the absence of a preventative 
vaccine or cure, the illness continues to affect millions of individuals. The United Nations AIDS 
(UNAIDS) organisation estimated that there were more than 43.9 million people living with HIV 
(PLHIV) worldwide at the end of 2018.3 In 2017, 22 million PLHIV were residing in Eastern and 
Southern Africa.3 Sub-Saharan Africa bears a significant global burden of PLHIV.3  
The introduction of combination antiretroviral therapy (cART) has changed the AIDS epidemic to a 
chronic, but manageable disease.4 Besides problems related to drug adherence, tuberculosis and HIV 
co-infections, cART has been constantly challenged by the development and spread of drug 
resistance. This poses a significant threat to the long-term management of PLHIV in public health 
settings where patients are often monitored using clinical or immunological parameters.5  
South Africa has one of the largest populations of PLHIV, with 7.1 million infected, thus accounting 
for 19% of the global number of PLHIV. HIV prevalence is high amongst the general population at 
18.9%, with approximately (61%) 4.5 millions of adults receiving cART.3 In 2016, the South African 
government adopted the UNAIDS test and treat, and the 90-90-90 strategy. This strategy aims at 
having 90% of infected individuals diagnosed by 2020, providing cART to 90% of those diagnosed 
and achieving viral suppression for 90% of those on cART by 2020.3 South Africa has made progress 
towards the first UNAIDS 90% target, but progress towards the second and the third 90% targets has 
been less impressive. Achieving the 90-90-90 target will require that at least 80% of PLHIV are on 




1.2. Research question and study aim 
In South Africa, due to its high cost, genotypic resistance testing is not widely available for treatment-
naïve patients and/or newly infected patients. The World Health Organization (WHO) supports 
transition to integrase strand transfer inhibitors (InSTIs)-based first-line treatment regimens in 
regions such as South Africa where pre-treatment drug resistance to non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) reaches 10% 3. With more people becoming eligible for cART, can 
pre-treatment or acquired mutations that confer resistance to nucleoside reverse transcriptase 
inhibitors (NRTIs) and NNRTIs affect the efficacy of an InSTIs-based regimen? To combat resistance 
challenges, a combination of two NRTIs and a third agent, either an InSTI, a boosted protease 
inhibitor (bPI) or an NNRTI, is needed. The cART approach, using three to four antiretrovirals, was 
designed to prevent the virus from developing escape mutations and to target HIV-1 at different 
replication stages. The main aim of my study was to investigate the prevalence of InSTI mutations in 
treatment-naïve and treatment-experienced PLHIV using genotypic assays, which included Sanger 
sequencing, next-generation sequencing (NGS) and molecular modelling. In addition, we also 
generated Long Terminal Repeat (LTR) HIV-1 sequences to identify transcription factor binding 
sites. NF-κB plays an important role in regulating the viral gene expression from the viral promoter 
and controlling viral latency. 
1.3. Study objectives 
Objective one: To identify the HIV-1 resistance mutation profiles of patients against available first- 
and second-generation InSTIs in treatment-naïve patients prior to the launching of the South African 
national HIV-treatment programme (Paper 1 – published). 
Objective two: To identify the HIV-1 resistance mutation profiles of patients failing second-line 
cART regimens in South Africa (manuscript under review by Nature – Scientific Report. Reference 
number: SREP-19-20242). 
Objective three: To perform NGS of the HIV-1 integrase (IN) gene fragment from South African 
patients failing second-line cART regimens, using the HiSeq 2500 sequencing system (Illumina) 
(manuscript under review by Journal of Antimicrobial Chemotherapy. Reference number: JAC-2019-
1065). 
Objective four: To explore the structural impact of IN polymorphisms from diverse HIV-1 subtypes 





Objective five: To explore the consensus wild type subtype C IN sequence to build an accurate 3D 
model of HIV-1C IN. This is in order to understand the effect of three statistically enriched mutations 
on DTG drug binding (manuscript submitted to PLOS One). Pre-print available: http://biorxiv.org/c
gi/content/short/781120v1. doi: https://doi.org/10.1101/781120 
Objective six: To analyse LTR sequences from HIV participants in order to identify transcription 
factor binding sites. NF-κB in regulating the viral gene expression from the viral promoter and 





1.4. Origin and history of HIV infection  
The lentivirus genus is a subset of the Retroviridae family of ribonucleic acid (RNA) viruses. AIDS 
was initially described as an immune deficiency state that was associated with multiple microbial 
infections and was commonly associated with homosexual patients in the early 1980s.7,8 In 1983, the 
viral agent was isolated from a lymph node biopsy of a Kinshasa patient; as a result, the causative 
agent HIV was initially termed ‘lymphadenopathy-associated virus’ (LAV).9 LAV was later termed 
‘human T-lymphotropic virus’ (HTLV)-III as the viral structure was similar to that of HTLV-I.10 In 
1986, HTLV-III was determined to be the causative agent of AIDS, but due to immune depletion, it 
was later named as HIV type 1 (HIV-1).10,11. The first evidence of HIV infection was found in a serum 
sample stored from 1959 obtained from a male in Kinshasa. HIV was found to be closely related to a 
simian immunodeficiency virus (SIV) strain that originated from chimpanzees of the subspecies Pan 
Troglodytes and was classified as HIV-1 in 1998.12 In 1960 a lymph node biopsy of a female stored 
in Leopoldville was recovered and analysed.13 Comparison of HIV-1 sequences in the 1959 and 1960 
samples showed a genetic variation of 12%. These findings suggested that HIV-1 had been present 
in humans before 196013 and possibly originated from multi-cross-species transmissions of SIV from 
primates to humans in Central and West Africa.14  
1.5. Virion structure and genome organisation  
The HIV-1 virion is surrounded by an external bilayer membrane and is cylindrically shaped, as 
shown in Figure 1.1. It is approximately 120 nm in diameter.10,15 The Envelope protein is covered 
with the outer trimeric surface glycoprotein (gp120) and transmembrane glycoprotein (gp41), derived 
from the precursor protein (gp160). A Matrix (MA) protein (p17) appears on the inside of the lipid 
bilayer shell, which forms the inner surface. The Capsid (CA) protein (p24) layer forms the conical 
capsid.16 The genome is a full-length diploid linear RNA.17 HIV-1 enzymes encoded by the HIV 
genome are Protease (PR), Reverse transcriptase (RT) and IN. Figure 1.1 B displays the HIV-1 
genome, which contains nine unique genes and encodes with various structural and non-structural 
viral proteins. These encoded viral proteins and enzymes play a crucial role in viral replication and 
establish infection in the host cell. HIV-1 also has regulatory genes called transactivator of 
transcription (tat) and regulatory of virion expression (rev). HIV-1 enzymes encoded by the HIV 
genome are Protease (PR), Reverse transcriptase (RT) and IN. Accessory genes include viral protein 






Figure 1.1 Schematic and Genetic Organisation of the HIV-1 (A and B). A) The diagram gives a 
transectional view of the HIV virion and displays the virus matrix encloses the capsid, which protects 
the two copies of genomic RNA, Protease, Reverse Transcriptase and Integrase. The Envelope 
consists of protruding glycoprotein gp120, which stems from the Fusion protein gp41. B) Genetic 
organisation of the HIV genome (approximately 9.7kb) showing the three main structural genes gag, 
pol and env. Regulatory (tat, rev) and accessory genes (vif, vpr, vpu, nef) genes. All these genes are 
necessary for effective HIV replication. (Adopted from Los Alamos HIV database, www.lanl.gov 
accessed on 17 May 2019). Reprinted with permission. 
1.6. The HIV life cycle and antiretroviral drugs  
Viruses depend on living hosts to replicate. The pol-encoded viral enzymes that are essential for viral 
replication are PR, RT (this includes a polymerase and an RNAse H domain) and IN. Antiretroviral 
drugs target these viral enzymes and inhibit stages in the viral lifecycle to reduce the host’s cellular 
function and replication steps. The Envelope protein of HIV-1, gp120, binds to CD4+ T-cell receptors 




5 (CCR5) and chemokine receptor 4 (CXCR4). After co-receptor binding, the gp41 Envelope protein 
undergoes a conformational change that enables the fusion of the viral membrane with the host cell 
membrane. At this stage, the viral capsid is released into the cytoplasm where uncoating begins. 
Thereafter, p24, which is the major Capsid protein, dissociates. The RT complex containing pol-
encoded viral enzymes (RT, RNAse H and IN) remains intact to the two copies of viral RNA.18 
Reverse Transcription is the first step of the HIV replication cycle. RNA is transcribed to an RNA-
DNA duplex, catalysed by the RT enzyme. The RNA is digested by RNAse H, followed by synthesis 
of double-stranded DNA through the DNA-dependent DNA polymerase activity of RT. The newly 
synthesised double-stranded DNA is transported through an active mechanism involving pre-
integration complex (PIC) that contains IN and CA proteins. IN cleaves the host’s chromosomal 
DNA, and the viral DNA is inserted into the host’s chromosomal DNA, now referred to as ‘proviral 
DNA’. At this stage, the virus can stay latent for years and establish a viral reservoir. RNA polymerase 
II catalyses the transcription of viral genes into viral messenger RNA (mRNA) or full genomic viral 
RNA, which is exported to the cytoplasm using host cell machinery. At this point, cellular ribosomes 
translate viral mRNAs into viral proteins. Viral proteins self-assemble during a process referred to as 
assembly. Upon maturation, the Gag protein is cleaved into the Matrix, Capsid and Nucleocapsid to 
form an infectious particle. In order for viral particles to mature to full infectivity, twelve (12) 
proteolytic reactions are needed.19 In precursor proteins, Protease cleavage occurs at a particular 
site(s) and this process results in mature virions that are capable of infecting another cell, resulting in 
repeated cycles of viral replication. The main steps of HIV viral replication – binding and entry, 
reverse transcription, integration, viral assembly and budding form the basis for the targets of the six 







Figure 1.2 The HIV lifecycle. The stages of viral lifecycle shown above. Thin, dark arrows show 
entry and integration. Curved and slightly bent arrows show early and late replication. 1- A piece of 
genetic material surrounded by protein. 2- Adsorption to the CD4 receptor (CXCR4 or CCR5). 3- 
Fusion and un-coating of a viral genomic dimer. 4- Reverse transcription. 5- Integration of pro-viral 
DNA into host genome using the integrase enzyme. 6- Transcription of viral DNA Nuclear import 
of PIC. 7- Assembly of viral chain 8- Viral budding, protease enzyme starts the formation of a new 
virus. 9- Breaking off the immature virus. 10- Viral maturation and formation of the new virus 





1.7. Mechanisms of HIV-1 drug resistance 
HIV drug resistance (HIVDR) emerges through different pathways, depending on the drug regimen. 
The goal of the treatment regimen is to preserve a functional immune system in PLHIV through 
suppression of HIV replication. In order to achieve this, cART is designed to target essential steps of 
the viral lifecycle. This section briefly explains the main mechanisms that can lead to resistance to 
each of the main drug classes. 
1.7.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
HIVDR to NRTIs mainly develops by two different mechanisms: discrimination and excision. In the 
discrimination mechanism, specific mutations enable RT to discriminate between the natural 
deoxyribose nucleotide triphosphate (dNTPs) and NRTI-TPs used during DNA replication, thus 
preventing the incorporation of the NRTI-monophosphate into the growing DNA strand.20 Mutations 
responsible for such resistance are M184V/I, K65R, 70E/G, L74V, Y115F and the rare Q151M 
complex.20–22 The most common discrimination mutation is M184V/I, which alone confer resistance 
to lamivudine (3TC) and emtricitabine (ETR).22,23 Furthermore, NRTI resistance mechanism, 
involves the incorporation of adenosine triphosphate (ATP)-mediated phosphorolysis which 
facilitates the removal of NRTIs from the 3’-end of the DNA. Thymidine analogue resistance 
associated mutations (TAMs) confer resistance through this mechanism.21 TAMs are primarily 
selected for by zidovudine (AZT) and stavudine (d4T); these are structural analogues of the cellular 
nucleotide thymidine.24 TAMs develop along two characteristic patterns: TAM 1 (41L, 210W and 
215Y) and TAM 2 (67N, 70R and 219E/Q).25–27 Mutations can also arise as a result of induced 
diversification of apolipoprotein B mRNA-editing enzyme and catalytic polypeptide 3G/F 
(APOBEC3G/F).28,29 The viral protein vif plays a vital role to inhibit APOBEC3G/F activity and in 
some cases can lead to certain levels of nonlethal genetic diversity.28,29 Such diversity can result in 
the development of mutations that confer resistance to 3TC.30 
1.7.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
The NNRTI resistance associated mutations (RAMs) are mostly located with the hydrophobic pocket 
in the RT. Resistance to NNRTIs develops relatively easy.20 These mutations can cause either 
alteration to the size of the binding pocket or physical changes to the structure of the binding pocket 
and thus prevent drug binding. A single NNRTI mutation alone is enough to confer resistance to 
several of the NNRTIs. The K103N mutation is the most common among patients receiving efavirenz 




resistance to EFV, rilpivirine (RPV) and NVP.31 Mutations E138K and M184I confer high-level 
resistance to both etravirine (ETR) and RPV32 
1.7.3. Protease inhibitors (PIs) 
Resistance to Protease inhibitors (PIs) is complex, and for ritonavir-boosted PIs, it requires the 
development of at least two mutations (either one or more major and one or more complementary) in 
the PR gene.20 It also involves mutations in the Gag gene.27,33 The binding of PR to its polyprotein 
target can be affected by major mutations in the PR gene.22 Drug resistant mutations may reduce the 
viral fitness, whilst compensatory changes can repair lost fitness. Minor PI mutations are often 
referred to as compensatory mutations and are very common.34 Minor PI mutations can improve viral 
fitness, and in the absence of major PI mutations, they have little effect on treatment outcomes.34 bPIs 
have a higher genetic barrier as compared to NRTIs and NNRTIs. This could be because the 
development of resistance requires more than one mutation. This has led to suggestions that 
virological failure in patients on bPIs mostly occurs in patients who do not adhere to their treatment 
regimen, rather than as a result of drug resistance.20 
1.7.4. Entry inhibitors 
Resistance to maraviroc, a CCR5 receptor antagonist, mostly occurs through a shift in co-receptor 
usage by the virus or through a shift in the viral envelope that enables binding to the CCR5 receptor, 
despite the presence of the inhibitor.35 At the start of a treatment regimen, changes would most likely 
occur if there is a mix of R5 and X4 tropic viruses.20 Existing data indicate that changes in the viral 
Envelope are mostly likely a common cause of maraviroc resistance.35 Resistance to enfuviritide (a 
fusion inhibitor) can develop through mutations in a domain of 10 amino acids.22,35 However, entry 
inhibitors are not part of standard therapy and these regimens are rarely used in South Africa.35 
1.7.5. Integrase strand transfer Inhibitors (InSTIs) 
Due to the important role of IN in the HIV-1 lifecycle, it has been targeted as part of cART. All 
InSTIs target the strand transfer reaction, which is catalysed by the viral IN. They are thus referred to 
as either Integrase Inhibitors (INIs) or InSTIs.36,37 InSTIs have two mechanisms of action: they bind 
only to the specific complex between IN and viral DNA, and they interact with the two essential 
divalent cations in the integrase active site in the presence of DNA. 38 InSTIs were first approved for 
clinical use in 2007 for the treatment of PLHIV. In terms of safety, tolerability, fast viral clearance 
and high potency, these classes of drugs have remarkable superiority over the other drug classes.39 
Currently, four InSTI drugs are approved: raltegravir (RAL), elvitegravir (EVG) dolutegravir (DTG) 
and bictegravir (BTG). Another InSTI cabotegravir (CAB) is in the advanced stages of clinical 




countries, they have become the preferred first-line regimen and are recommended by ART 
guidelines.40,41 
Due to high cost, access to InSTIs in low-middle income settings has been limited. Recent 
negotiations and agreements have led to the generic development of DTG and its adoption into WHO 
guidelines as an alternative first-line regimen.42 To date, in sub-Saharan Africa, only Botswana and 
Kenya have administered DTG as part of their standard first-line cART. The recent WHO guidelines 
recommend DTG as the preferred first-line regimen in regions where the prevalence of pre-treatment 
NNRTI resistance is ≥ 10%. As countries adopt the guidelines and generic drugs become more readily 
available, wide-scale access across the region is anticipated.43  
Even though these drugs are highly efficient, resistance to InSTIs has nevertheless been observed, 
which ultimately can lead to treatment failure.44,45. Some of these identified polymorphic mutations 
play a significant role in increasing the level of resistance and/or rescuing viral fitness. Primary 
mutation pathways identified involve substitutions at the T66, E92 (EVG), Y143 (EVG plus RAL), 
Q148, N155 and R263 (EVG, RAL and DTG) amino acids.46 Several biochemical studies have shown 
subtype-dependent influence of natural polymorphisms on the occurrence and activity of InSTI 
resistance.47–51,52 For example, subtype B viral strains associated with G118R have a higher fitness 
cost, recently proposed resistance pathway compared with subtypes C and CRF_02 AG.48 
Consequently, in subtype B viral strains, G118R has been rarely observed. It has been suggested that 
G118R could be an alternative pathway for DTG resistance in non-subtype B viruses, whereas R263K 
is the preferred pathway for subtype B viruses.48 In vitro studies, have shown that mutations located 
outside the IN gene, can confer a high-level resistance to all InSTIs. Because of this, HIV-1 can use 
an alternative mechanism route to develop resistance to InSTIs by selecting mutations in the 3’ PPT 
region.51,53 A rare polymorphism at codon 118 (GGG or GGA) has a low genetic barrier through a 
single mutation to facilitate the transition of glycine to arginine (AGG or AGA), which in turn has an 
impact on the occurrence of G118R.54 Furthermore, the prevalence of the G118R mutation may also 
differ by subtype but the impact of other polymorphic mutations in the resistance and viral fitness of 
G118R mutants was shown to be subtype dependent.49 In South Africa, a study conducted by Brado 
et al., 52 identified the prevalence of Q148H in 1/314 (0.3%) if co-occurring with additional RAMs. 
This mutation can lead to resistance against all InSTIs.52 
1.8. Combination antiretroviral treatment Mechanism of action 
The classes of cARTs based on the different targets of the HIV replication cycle  involves different 




1.8.1. Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) 
NRTIs gains entry into the cell by passive diffusion. NRTIs can be transported by a variety of carrier 
and ATP-dependent mediated membrane transporters. 55 NRTI phosphorylation is catalyzed by the 
action of phosphotransferases and cellular kinases into triphosphate forms. 56 NRTI triphosphate 
forms actively compete with the cell’s natural dNTP substrates at HIV-1 RT’s polymerase active site 
for incorporation into the growing cDNA strand, synthesized by HIV-1 RT enzyme. Once 
incorporated the triphosphate forms cause premature chain termination as they lack a 3’- OH group 
that would have facilitates the incorporation of the next dNTP substrate.57 
1.8.2. Non-Nucleoside reverse transcriptase inhibitors (NNRTIs) 
NNRTIs gain entry to the cell by passive diffusion as highly lipophilic molecules.58 Three different 
mechanism of action express antiviral activity. The first mechanism is  the allosteric inhibition – 
NNRTIs bind in a HIV-RT pocket region. The polymerase active site is 10Å away from the pocket 
region and cause a conformation change in HIV-RT, a result this affect its ability to bind to the primer 
during reverse transcription.59 The second mechanism (although controversial) involves the 
enhancement of the HIV-1 RT heterodimer formation. This inhibition downregulate the enzyme’s 
activity to simultaneous executes its polymerase and RNA degradation functions. 58, 60 The third 
mechanism involves the acceleration of cytoplasmic Gag-Pol processing, which leads to the 
premature activation of the HIV-1 Protease. Premature activation of the Protease  occurs when 
binding of NNRTIs to Gag-Pol proteins promotes oligomerization of the Pol molecules by binding to 
the p66 subunit of HIV-RT. Premature cleavage of these Gag-Pol constructs restricts proteins 
required for viral particle assembly 58 
1.8.3. Protease Inhibitors (PIs) 
PI cellular entry can be mediated by Clathrin / Caveolae endocytic pathways or via passive diffusion 
61 The tight binding interactions of the PI on the dimer surface of the homodimer HIV-1 Protease 
active site inhibits its function to execute aspartic acid- mediated cleavage of its substrates.62 This  
reduces the rate of viral assembly or production of defective viral particles unable to establish another 
round of infection 63 
1.8.4. Integrase strand transfer inhibitors (INSTIs) 
InSTI enter the cell by endocytic adsorption. Once in the cytoplasm, they are able to bind to the 
Integrase, but only access the enzyme’s active site once there has been a conformational change 
induced, after the enzyme catalyzes the 3’-end processing reaction.64 The 3’-end processing reaction 
exposes a dinucleotide (CA) at the end of the viral cDNA that will eventually allow for integration 




nucleus, Integrase requires divalent Magnesium ions to stabilize its active site, but these metal ions 
are sequestrated by INSTIs that have a β-diketo acid group (as part of their structure) that has high 
affinity for the divalent metal ions 46. 
1.9. Human immunodeficiency virus treatment and the combination antiretroviral 
therapy roll-out programme in South Africa 
1.9.1. In adults 
South Africa launched a national cART rollout programme in 2004. Since its initiation, South 
Africa’s national HIV treatment programme has grown to become the biggest in the world with an 
estimated 4.5 million people currently receiving treatment.65 In concordance with the WHO 
guidelines, the recommended first-line cART in South Africa consists of an NNRTI-backboned 
regimen of EFV combined with two NRTIs, namely 3TC and tenofovir disoproxil fumarate (TDF) 
for adults. The recommended second-line cART consists of the NRTIs AZT and 3TC and a ritonavir-
boosted PI, usually atazanavir (ATV).66   
 
1.9.2. In Children  
The South African guidelines recommend for children ≤ three years that first-line cART consist of a 
LPV/r and two NRTIs, namely abacavir (ABC), 3TC. For children ≥ three years and ≥ 10 kg, the 
first-line cART regimen includes ABC, 3TC and EFV. For adolescents ≤ 15 years, the regimen 
contains TDF, emtricitabine (FTC) or 3TC and EFV. If viral load is undetectable (< 50 RNA 
copies/mL), patients currently receiving a d4T-based regimen can be changed to ABC. The WHO 
guideline also recommends the PI lopinavir co-formulated with ritonavir (lopinavir–ritonavir) in a 
four-to-one ratio in first-line cART for children younger than three years, based on its superiority 
compared with NVP, regardless of previous NVP exposure to prevent mother-to-child HIV 
transmission.66 For children who have failed the first-line PI-based LPV/r regimen, experts must be 
consulted and resistance testing in patients > 12 months and adherent to treatment must be considered. 
Children who have failed the NNRTI-backboned regimen of EFV or NVP must be changed to an 
NRTI-backboned regimen of LPV/r.  
1.9.3. When to initiate combination antiretroviral therapy 
The question of when to initiate cART has long been the subject of intense debate.67–69. Initially, 
cART was recommended for only symptomatic PLHIV. The hit-hard-and-hit-early strategy covered 
a large percentage of asymptomatic PLHIV with HIV RNA > 10 000 RNA copies/mL or a CD4+ T-




a shift in guidelines, postponing therapy until CD4+ T-cells declined to < 350 cells/µL. Clinical trials 
identified benefits for those initiated on cART with a CD4+ T-cell count around 350-500 cells/µL as 
opposed to < 350 cells/µL.71,72 The outcome of these trials  led the WHO to again reconsider its 
guidelines to cART initiation at a CD4+ T-cell count ≤ 500 cells/µL.73  
International randomised clinical trials and the Strategic Timing of Antiretroviral Treatment 
(START) study provided compelling evidence of the importance and benefits of starting cART as 
soon as possible after HIV diagnosis.74 This evidence gave birth to new guidelines that recommended 
that all PLHIV be initiated on cART regardless of their CD4+ T-cell count.74 Early initiation of cART 
have clinical benefits, but do not necessarily reduce the size of the HIV reservoir. A study conducted 
by Cirion et al 75 identified 14 elite controllers (these patients were able to control their infection 
without using cART) after three years of cART initiated during primary HIV infection. In this study, 
the researchers showed that viral control with therapy, for several years, might be associated with 
early and prolonged cART. Their findings support the initiation of early cART. Early cART also 
limits the genetic diversity within HIV DNA reservoirs,76,77 improves survival78 and reduces the risk 
of HIV-1 transmission.79  
1.9.4. Role of an extra κB transcription factor in HIV-1C LTR gene 
Globally, HIV-1 subtype C (HIV-1C) is responsible for more than 75% of new infections and 50% 
of infections 1. In South Africa, HIV-1C is responsible for the majority of infections. HIV-1 subtype 
C, unlike other HIV-1 subtypes, has a considerable variation in the number of NFkB sites 80 and 
most of the molecular variations are linked to the viral promoter, where host and viral transcription 
factors bind to regulate viral transcription 81. The LTR is an important regulatory gene region for the 
viral life cycle and the HIV-1 promoter, located at the 5’ LTR, contains several transcription factor-
binding sites (TFBS). The HIV-1C LTR has the most genetically divergent sequences. One of the 
most significant genetic variations associated with the ancestral subtype C is the presence of three 
NFkB motifs in the LTR 82. In most HIV viral subtypes, including subtype B, only two genetically 
identical NFkB motifs are present. 83 NFkB is a key nuclear transcription factor involved in HIV-1 
transcription, triggering the viral replication through TAT/TAR mediation. Variation in LTR was 
observed in Circulating Recombinant Form (CRF-01), whereby NFkB was replaced by a GA binding 
protein (GABp) motif. The ancestral subtype C viruses contains three NFkB sites, but we have 
observed that at least three different promoter variants have been replacing the ancestral subtype C 
84. These viral strains contain additional NFkB, NFkB-like or RBEIII sites and the acquisition of an 
additional NFkB site remains a distinct property of the HIV-1C. As a result, this might strengthen the 




that the acquisition of a 4th NFkB site by emerging strains can lead to more infectious pathogenic 
strains 84,85,86,88. In this thesis, we characterized the genetic variation in HIV-1 LTR from subtype C 
sequences derived from South African PLHIV-1.  
1.10. In-silico integrase analyses  
Computational approach was explored to the study of HIV-1 IN structure such as the usage of 
homology modelling, molecular docking and molecular dynamics have been very instrumental in 
studying the functional and structural details of HIV-1 IN.  
1.10.1. Homology Modelling 
Homology modelling also referred to as comparative modelling, is a computational method which is 
used to generate a structural model of a protein 89. This method relies upon the observation that similar 
sequence implies similar structure. Provided with an experimentally solved structure, it is possible to 
generate a reliable homologous structure from an experimentally solved structure that has a sequence 
similarity of 30% or greater 89. 
Homology modelling has played a major role in drug discovery and development 89. Homology 
modelling has been used to gain structural understanding and drug development insights into HIV-1 
IN. Early models exploited the homology shared with TN5 transposase to generate an homology 
model. One such Tn5 based  homology model study found that residues 140-149 represents a mobile 
catalytic loop, the study also showed that residues responsible for DNA binding are highly conserved 
90. This mobile loop would be further studied in additional in-silico work as it plays key roles in drug 
resistance 48. The experimental solving of the Protype Foamy Virus (PFV) IN protein provided a new 
structure for which reliable homology could be generated 91–93.The IN active site in the catalytic core 
of each integrase is nearly identical. As a result of this high identity it is possible to bind InSTI’s to 
PFV integrase, this enabled an accurate understanding of how InSTI’s may bind to HIV-1 IN and the 
effect of resistance mutations upon this binding 94.Models were also generated using domains of the 
IN proteins as the starting homologous structure from which to model. A study have shown that there 
is dimer interface between the integrase N-terminals was observed 95. The Cryo-EM solving of a full 
length tetrameric HIV-1 integrase complex has made it possible to produce highly plausible full 
length homology models 96.Studies have used this model as a template to generate an homology 
model, polymorphisms unique to certain subtypes have been investigated 52,97. It was possible to 




1.10.2. Human Immunodeficiency virus reservoir during combination antiretroviral therapy 
and reservoir establishment 
The first documentation of a latent HIV reservoir was reported in 1997 by three groups (Chun et al., 
Finzi et al., and Wong et al.,69–71) This group of scientists stimulated viral production from cART 
individuals with undetectable viral load, using their peripheral resting CD4+ T-cells.69–71. Viral 
integration into the host DNA enables HIV to exist as a provirus through the suppression of viral 
expression. HIV reservoirs remain the major barrier to HIV cure as they persist and give rise to viral 
rebound in plasma once there is any interruption of cART.72 Although HIV reservoirs are diverse and 
dynamic, HIV reservoirs in the memory CD4+ T-cells are considered as the major barrier to a cure. 
Two pathways through which HIV infects memory CD4+ T-cells have been hypothesised: through 
the infection of activated CD4+ T-cells that survive and revert to a memory phenotype, and via direct 
infection of and integration into the genome of the resting memory CD4+ T-cells.  
1.11. Methods to test for drug resistance 
The two main methods available to test for HIV-1 drug resistance are the genotypic and phenotypic 
methods. There are different genotypic approaches available to detect drug resistance mutations 
(DRMs), but in this study, I used direct population-based sequencing and Next Generation 
Sequencing (NGS). Genotypic resistance testing (GRT) involves the detection of known resistance 
mutation in the genes of HIV-1, which confers limited susceptibility to cART. 
1.11.1. Population Based Sanger Sequencing 
This approach is based on direct polymerase chain reaction (PCR) followed by Sanger 
(dideoxynucleotide) sequencing. In South Africa, this method is the most preferred and forms part of 
standard of care to guide cART regimen prescription and, most importantly, to monitor DRMs in 
PLHIV. Direct sequencing can be performed using either commercially available kits or in-house 
methods.73,74 These assays are capable of producing a complete genome nucleotide75. The obtained 
virus sequence is a consensus sequence generated from a population of viral genomes, therefore the 
name ‘population sequencing’. In order to determine the presence of a possible DRM, derived viral 
sequences are aligned and compared to a reference sequence of a laboratory wild-type strain. 
Clinically relevant mutations can be determined by using the Stanford drug resistance database.20,76 
According to the international guidelines, population-based sequencing is recommended as the 
standard GRT approach to monitoring DRMs77; however, these approaches have their limitations. 
First, they are not sensitive enough to detect viral populations below 20% of the total viral population, 
which may allow clinically relevant minor variants to become undetected. In high-income countries, 




not cost-effective and not easy to implement. Second, interpretation of the viral sequence is complex 
and it is challenging and time-consuming to apply distinct viral mutations to cART management. 
Alternatively, more sensitive GRT has been developed, such as deep sequencing (NGS), which could 
be used as an option in resource-limited settings by targeting key DRMs.  
1.11.2. Next-Generation Sequencing (NGS) 
NGS platforms have revolutionised the field of sequencing and have made it possible to generate high 
throughput of sequence data from biological systems in a single reaction run. There are different 
platforms accessible for deep sequencing, such as Illumina, Ion Torrent and the Nanopore DNA 
sequencing technology. Due to cost and maintenance requirements, their availability has been limited. 
The introduction of benchtop sequencing platforms with the benefit of high-throughput data has been 
shown to be cost-effective and less time-consuming compared to the conventional population-based 
sequencing approach106 and might be a more suitable option in clinical diagnostics. The sequencing 
approach in the Illumina MiSeq platform is characterised by synthesis technology that enables 
tracking of fluorescently labelled nucleotides as they are added in a parallel mode to the DNA strands. 
Illumina MiSeq, as compared to the other NGS platforms, has been shown to be more advantageous 
in terms of simpler laboratory workflows, reduced hands-on time and deeper sequencing coverage to 
detect single polymorphisms with minimum error rate.107,108 Several studies have shown that the 
Illumina MiSeq platform is cost-efficient to generate high-throughput data and is a promising 
approach for the surveillance of primary DRMs in low-to-middle-income settings (LMICs).109–111 
1.11.3. Phenotypic resistance testing 
Phenotypic resistance can be referred to as resistance against cART regimen, which can be detected 
in viral culture as a reduction in susceptibility of a molecular clone or an isolate to any of the classes 
of cART treatment regimen in comparison to a standard viral isolate or molecular clone. Genotypic 
testing of HIV-1 viral strains can be used to infer phenotypic resistance. Phenotypic testing was 
developed when an HIV isolate was cultured in a CD4-expressing HeLa cell line and the reduction 
of syncytial foci in the presence of AZT was associated with the degree of AZT susceptibility 112. 
This assay is only limited to be used for syncytium-inducing isolates that can only be found late in 
disease. This led to the development of an assay based on co-culture of infected cells with peripheral 
blood mononuclear cells (PMBCs) from HIV negative donor, which could detect anon-syncytium-
inducing isolates 113. In previous years, viral culture and co-culture requires biosafety level 3 facilities. 
The biosafety level 3 is required to protect laboratory technologist. Due to the development of reporter 
cell lines transfected with non-infectious plasmid vectors with inserts from the patient-derived RT 




 The results of this thesis are summarised in the following chapters: 
1. Chapter two: Analyses of HIV-1 integrase sequences prior to South African national HIV-
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Chapter 2 Analyses of HIV-1 integrase sequences prior to South African 
national HIV treatment program and availability of integrase inhibitors in 
Cape Town, South Africa. 
2.1. Article title 
Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and 
availability of integrase inhibitors in Cape Town, South Africa. Permission to use as part of thesis 
was granted by Editor on 29.05.2019. 
2.2. Authors list and citations 
Brado D, Obasa AE, Ikomey GM, Cloete R, Singh K, Engelbrecht S, Neogi U, Jacobs GB.  
Number of Citations: 6 
Scientific Reports. 2018 Apr 16;8(1):6262. doi: 10.1038/s41598-018-24183-8. PMID: 29549274.  
2.3. Author contribution 
In the enclosed manuscript; Mr. Brado and I, are joint-first authors, with equal contributions to the 
work performed. Mr Brado was an undergraduate medical student for three months at the Division of 
Medical Virology as a DAAD intern. I retrieved the samples from the cold storage. I trained (assisted) 
Mr. Brado to perform the laboratory experiments, including Viral RNA extraction, polymerase chain 
reaction (PCR), PCR clean-up reactions and Sanger sequencing. Mr. Brado and I, performed the 
sequence and data analyses. I wrote the first draft and was responsible for subsequent manuscript 
updates received from the co-authors. 
2.4. Background 
Integrase strand transfer inhibitors (InSTIs) are highly efficacious and well tolerated antiretroviral, 
with fewer adverse side effects, relative to other classes of combination antiretroviral therapy (cART) 
drugs (or inhibitors). The use of InSTIs raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG) 
has increased dramatically over recent years. There is limited information about the evolution and 
prevalence of InSTIs resistance mutations in people living with HIV from South Africa. The cohort 
contains treatment-naïve patient samples from multiple ethnic groups, as well as different sexual 
orientations. Patients were sampled between 2000 and 2001, before the initiation of South Africa’s 




2.5. Main findings 
We identified 85 (92%) of our samples as HIV-1 subtype C (HIV-1C). The consensus sequences 
generated using the database-derived HIV-1CZA sequences (n = 314) and cohort sequences (n = 85) 
identified 17 naturally occurring polymorphisms. Among the 17 mutations, 11 were further increased 
our cohort. Genotypic analyses indicated the absence of major RAMs in the cohort collected before 
the broad availability of cART and InSTIs in South Africa. The database-derived sequences, InSTI 
occurred at a rate of 2.85% (9/314) in. RAMs were present at IN-positions 66, 92, 143, 147 and 148, 
all of which may confer resistance to RAL and EVG, but are unlikely to affect second-generation 
DTG, except mutations in the Q148 pathway. 
2.6. Study significance 
These are precious samples, as these patients were sampled nineteen (19) years ago, which means 
data generated from this study could be considered as baseline InSTIs resistance rate. As the analysed 
cohort was recruited before the initiation of the HIV treatment program in South Africa, the possibility 
of RAMs being transmitted by treatment-experienced individuals is highly unlikely. Therefore, we 
consider the described findings to be a true baseline InSTI resistance rate. There was no cART 
regimen when these patients were sampled, thus rules out the possibility of RAMs being transmitted 
amongst the treatment-experienced individuals. InSTIs have been introduced in South Africa, as a 
component of salvage therapy. Despite this, only a few studies have examined the IN gene in terms 
of viral genetic variability and resistance mutational patterns. Our study emphasizes on the need for 
proper drug resistance surveillance in future, in order to track the evolution of the virus in a subtype 
C predominated setting under the pressure of the new treatment. 
2.7. Conclusions 
The prevalence of InSTI resistance remains low in the treatment-naïve patients, but with the extension 
of InSTI as part of first-line cART regimen resistance toward this class of cART might increase. 
Furthermore, protein modelling showed, naturally occurring polymorphisms might influence the 
stability of the intasome-complex and therefore may contribute to an overall potency against InSTIs. 
2.8. Open access 
The article is open access and freely available online. Reprints can also be obtained from the author 
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Chapter 3 Drug resistance mutations against Protease, Reverse 
Transcriptase and Integrase inhibitors in people living with HIV-1 
(PLHIV) receiving second-line antiretroviral therapy on the South 
African National treatment program.  
3.1. Article title 
Drug resistance mutations against Protease, Reverse Transcriptase and Integrase inhibitors in people 
living with HIV-1 (PLHIV) receiving second-line antiretroviral therapy on the South African 
National treatment program.  
3.2. Authors list and citations  
Obasa AE, Mikasi SG, Brado D, Cloete R, Singh K, Neogi U, Jacobs GB. Manuscript submitted 
and under review by Nature – Scientific Reports. Manuscript Reference number: SREP-19-20242. 
3.3. Author contribution 
In the enclosed manuscript, I confirmed that I am the first author. I obtained the patient samples, 
performed the laboratory experiments, including Viral RNA extraction, polymerase chain reaction 
(PCR), PCR clean-up reactions and Sanger sequencing. I performed the sequence and data analyses. 
I wrote the first draft and was responsible for subsequent manuscript updates received from the co-
authors. 
3.4. Background 
In South Africa, 7.1 million people are infected and living with HIV, representing 19% of the global 
infected population. The South African national cART rollout program started in 2004, with over 4.5 
million accessing treatment by the end June 2018. HIV-1 drug resistance can hamper the success of 
cART. This chapter describes the patterns of RAMs against PIs, RTIs, and InSTIs from patients 
suspected of failing on the South African second-line national cART programme.  
3.5. Main findings  
Of the 96 sequences analysed (n= 52, 54%) had M184V/I as the most frequent NRTI RAM. The most 
frequent NNRTI RAM was K103N/S, which was identified in (n=40, 42%) patients E157Q was 
identified in (n= 2, 2%) patients as the most common InSTI RAM, alongside with T66I, Y143R and 




3.6. Study significance  
The majority of the patients had the M184V RAM.  This could have been carried over from first-line 
cART. Data generated from this study can assist in the development of cART guidelines for patients 
who experience treatment failure in resource-limited settings where genotyping is not available. We 
analysed the integrase gene for the presence of treatment-compromising polymorphisms and DRMs 
against InSTIs. We observed the presence of Y143R in combination with T97A in one of our patients 
receiving ABC, 3TC, LPV/r. N155H, Q148H/R/K and Y143R/C/H are the three major recognised 
pathways of genotypic resistance against InSTIs. 
3.7. Conclusion  
Our study showed patterns of RAMs against RTIs and PIs from patients suspected of failing on the 
South African second-line National cART program. We observed very low or no primary InSTI 
RAMs. Non-identification of any RAMs in one third of the patients and presence of PI RAM in only 






3.8. Manuscript under review by Nature – Scientific Reports 
Drug resistance mutations against Protease, Reverse Transcriptase and Integrase inhibitors in people 
living with HIV-1 receiving second-line antiretroviral therapy on the South African national treatment 
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The South African national combination antiretroviral therapy (cART) rollout program started in 
2006, with over 4.4 million people accessing treatment by the end of June 2018. HIV-1 drug 
resistance can hamper the success of cART. This study determined the pattern of HIV-1 drug-
resistance associated mutations (RAMs) after the suspected failure of first- and/or second-line cART 
regimens in South Africa. During 2017 and 2018, 96 patient plasma samples were selected, including 
those of 17 children and infants. All patients were receiving a boosted protease inhibitor as part of 
their cART regimen. The viral sequences were analysed for RAMs through genotypic resistance 
testing. Of the 96 polymerase sequences analysed, 52 (54%) had M184V/I like the most frequent 
nucleoside reverse transcriptase inhibitor RAM. The most frequent non-nucleoside reverse 
transcriptase inhibitor RAM was K103N/S, which was identified in 40 sequences (42%). Protease 
inhibitor RAMs M46I and V82A were present in 12 (13%) of the sequences analysed. The RAM 
E157Q was identified in two (2%) of the integrase sequences as the most frequent integrase strand-
transfer inhibitor (InSTI) RAM identified, along with one (1%) each of T66I, Y143R and T97A. We 
propose continued viral load monitoring for better management of infected patients. 
Keywords 
HIV-1; reverse transcriptase inhibitor (RTI); protease inhibitor (PI); integrase strand-transfer 
inhibitor (InSTI); resistance; South Africa; resistance-associated mutations (RAMs); combination 






Exceptional improvements in combination antiretroviral therapy (cART) regimens has changed 
HIV/AIDS from a deadly pandemic to a chronic and manageable disease 1. cART has made 
significant contributions to reducing the rates of morbidity and mortality in people living with HIV 
(PLHIV) and has led to better management of infection at an individual level, not only in high-income 
countries, but also in low- and middle-income countries 2,3. South Africa’s national HIV cART 
programme was introduced in 2006 with a public health approach. It is the largest in the world, giving 
treatment access to 4.4 million people by June 2018 4. Besides problems related to adherence, the 
development and spread of drug resistance has constantly challenged the long-term management of 
PLHIV in public health settings, where patients are often monitored using clinical or immunological 
parameters 5.  
In accordance with the World Health Organization’s (WHO) guidelines, the recommended first-line 
cART in South Africa consists of a non-nucleoside reverse transcriptase inhibitor (NNRTI) 
backboned regimen of efavirenz (EFV), combined with two nucleoside reverse transcriptase 
inhibitors (NRTIs), namely lamivudine (3TC) and either tenofovir disoproxil fumarate (TDF), for 
adults, or abacavir (ABC), for children. The recommended second-line cART consists of the NRTIs 
zidovudine (AZT) and 3TC and a ritonavir-boosted (/r) protease inhibitor (PI), usually atazanavir 
(ATV) 6. The WHO guidelines also recommend the PI lopinavir co-formulated with ritonavir 
(lopinavir/ritonavir [LPV/r]) in a four-to-one ratio in first-line cART for children younger than three 
years, based on its superiority when compared with nevirapine (NVP), regardless of previous NVP 
exposure to prevent mother-to-child HIV transmission 6.  
In vitro studies on PI-naïve PLHIV-1 subtype C, have indicated wide variations in their respective 
susceptibility to the PIs LPV/r and ATV 7. Observational studies from sub-Saharan Africa have shown 
a 14–32% prevalence of virological failure to second-line boosted PI- (bPI) based cART 8,9. In South 
Africa, reports of drug resistance patterns in patients receiving bPIs are scarce 10. With this study, we 
aimed to identify the pattern of acquired drug resistance mutations (DRMs) among PLHIV in South 
Africa receiving bPI second-line cART. Furthermore, we characterised the presence of primary 






In this study we included patients suspected of failing second-line cART regimens. We confirmed 
the successful amplification and Sanger sequencing of the protease, reverse transcriptase and 
integrase gene fragments of the HIV-1 polymerase gene for 96 samples. Figure 3.1. shows the 
observed DRMs in patients failing second-line cART. Among the patients, 10% (10/96) of the 
samples did not have an indicated in their patient file as being either male or female. Hence, they 
were classified as unknown. The ages ranged from 2 to 66 years. 
Seventeen (n = 17; 18%) of the patients were 16 years or younger. Of these patients, three (n = 3; 
3%) were female, 12 (13%) were male, while for two (2%) the gender had not been disclosed by the 
physician. The NRTI cART regimen combinations administered were ABC plus 3TC (n = 6; 6% of 
patients), AZT plus 3TC (n = 6; 6%), stavudine [d4T] plus 3TC (n = 1; 1%), TDF plus emtricitabine 
[FTC] (n = 1; 1%), ritonavir and truvada (n = 1; 1%) and TDF plus AZT (n = 1; 1%). Fourteen (15%) 
had received LPV/r, two (2%) had received ATV and one (1%) had received darunavir (DRV) as 
their bPIs.  
We had a total of 76 adults; 55 (57%) were women and 22 (23%) were men, while with two (2%) the 
gender was not disclosed by the physician. The most commonly used NRTI combination was AZT 
plus 3TC (n = 56; 58%), compared with those receiving ABC plus 3TC (n = 11; 11%) and TDF plus 
3TC (n = 8; 8%). Other regimens given were d4T plus 3TC (n = 2; 2%), truvada (n = 2; 2%), TDF 
plus etravirine [ETR] (n = 1; 1%) and AZT plus TDF (n = 1; 1%). Fifty-eight (60%) had received 





Figure 3.1 Observed drug resistance rates in patients receiving cART 
The observed DRMs in patients failing second-line cART. High-level resistance was shown in 17 
(17%) and 14 (14%) of PLHIV against LPV/r and (ATV), respectively, while seven (7%) showed 
intermediate cross-resistance to DRV. Despite not being NNRTIs based treatment more than half of 
the patients were shown to have high-level resistance to NVP (57%, n = 56) and EFV (56%, n = 55). 
NRTI resistance-associated mutations  
Table 3.1 shows the number of resistance-associated mutations (RAMs) observed among the 96 
sequences analysed. We observed M184V/I as the most prevalent NRTI mutation. M184V/I was 
detected in 52 (54%) patients suspected of failing cART. Of these, 36 (69%) patients were receiving 
a combination of AZT plus 3TC, compared with 13 (14%) patients receiving an ABC plus 3TC 
combination. M184V/I was also found in two (4%) patients receiving TDF plus 3TC, compared with 
those receiving FTC plus TDF (n = 1; 2%). L74V was detected in five (5%) patients – three (3%) 
patients receiving ABC plus 3TC, and two (2%) patients receiving AZT plus 3TC. The K65R/N 
mutation occurred in five (5%) patients; K65R occurred in two (2%) patients receiving AZT plus 
3TC, and in one (1%) patient receiving TDF plus FTC. The Y115F mutation occurred in five (5%) 
patients. However, Y115F occurred more often in patients receiving AZT plus 3TC (n = 4; 4%); it 
occured in one (1%) patient receiving ABC plus 3TC. The A62V mutation occurred in one (1%) 
patient receiving AZT plus 3TC. V75I occurred in one (1%) patient receiving AZT plus 3TC.  
Thymidine analogue mutations (TAMs) were grouped into TAMs1 and TAMs2. The most frequent 
TAMs observed were K70R/E in 10 (10%) patients receiving AZT plus 3TC, in three (3%) patients 
receiving ABC plus 3TC, and in one (1%) patient receiving FTC plus TDF. D67N occurred in five 




occurred in one (1%) patient receiving both TDF plus 3TC and an FTC plus TDF-based regimen. The 
K219E/Q mutation occurred in six (6%) patients receiving AZT plus 3TC, and in two (2%) patients 
receiving FTC plus TDF. The M41L mutation occurred in three (3%) patients receiving AZT plus 
3TC, and in one (1%) patient receiving 3TC plus ATV. T215Y occurred in two (2%) patients 




Table 3:1 Characteristics and patterns of mutations in 96 patients receiving bPIs  
Variable N (%) 
Gender 
 
Female 58 (60%) 
Male 34 (35%) 
Unknown 4 (4%) 
Second line treatment regimen 
AZT, 3TC, LPV/r 47 (49%) 
ABC, 3TC, LPV/r 17 (18%) 
TDF, 3TC, LPV/r 8 (8%) 
AZT, 3TC, ATV 6 (6%) 
TDF,FTC,LPV/r 5 (5%) 
Others 13 (13%) 
Major PI Mutations 
Any PI Major Mutations 18 (19%) 
>1 PI Major Mutations 17 (18%) 
I47A/V 3 (3%) 
I50L/V 2 (2%) 
I54V 10 (10%) 
I84V 7 (7%) 
L76V 7 (7%) 




V32I 2 (2%) 
V82A 12 (13%) 
Major NRTI resistance mutations 
Any NRTI Mutations 65 (68%) 
>1 NRTI Mutations 30 (31%) 
M184V/I 52 (54%) 
T69D 2 (2%) 
L74V 5 (5%) 
K65R/N 5 (5%) 
Y115F 5 (5%) 
TAM-1 pathway 
 
M41L 4 (4%) 
T215Y 2 (2%) 
TAM-2 pathway 
 
D67N 11 (11%) 
K70R/E 17 (18%) 
K219E/Q 11 (11%) 
Major NNRTI resistance mutation 
Any NNRTI Mutations 62 (65%) 
>1 NNRTI Mutations 41 (43%) 
Y181C 1 (1%) 
K103N/S 40 (42%) 




K101EP 6 (6%) 
E138AGKQ 11 (11%) 
H221Y 2 (2%) 
M230L 1 (1%) 
P225H 14 (15%) 
V106M 13 (14%) 
V108I 3 (3%) 
Y188L 8 (8%) 
L100I 2 (2%) 
TAMS* 45 (47%) 
D67N, M41L, T215Y/F, K219E/Q, K70R, and L210W 
M184V and TAMS 15 (16%) 
Integrase (IN) mutations 
Major IN mutation 
T66I 1 (1%) 
Y143R 1 (1%) 
Y143R and T97A 1 (1%) 
IN Accessory mutations 
E157Q 2 (2%) 





NNRTI resistance-associated mutations 
Table 3.1 shows the number of NNRTI RAMs observed. We observed that the K103N/S mutation 
occurred in 41 (43%) of those patients failing cART. Of the patients with this mutation, 24 (59%) 
patients were receiving AZT plus 3TC, and five (5%) patients were receiving ABC plus 3TC. P225H 
occurred in 10 (10%) patients receiving AZT plus 3TC, in three (3%) patients receiving ABC plus 
3TC, and in two (2%) patients receiving TDF plus 3TC. V106M occurred in 10 (10%) patients 
receiving AZT plus 3TC, and in two (2%) patients receiving ABC plus 3TC.  
Y188L occurred in five (5%) patients receiving AZT plus 3TC, and in two (2%) patients receiving 
TDF plus ATV, and in one (1%) patient receiving ABC plus 3TC. G190G/A occurred in six (6%) 
patients receiving AZT plus 3TC, and in three (3%) patients receiving ABC plus 3TC. K101EP 
occurred in three (3%) patients receiving AZT plus 3TC, and in one (1%) patient receiving ABC plus 
3TC. E138QGA occurred in four (4%) patients receiving AZT plus 3TC, in three (3%) patients 
receiving ABC plus 3TC, and in one (1%) patient receiving TDF plus 3TC. V108I occurred in one 
(1%) patient receiving AZT plus 3TC. H221Y and M230L occurred in one (1%) patient each; both 
these patients were receiving AZT plus 3TC. 
PI resistance-associated mutations 
Of the 96 patients, 75 (81%) were receiving the LPV/r-containing regimen, followed by the ATV- 
(n = 8; 8%) and DRV- (n = 4; 4%) containing regimens. We identified 18 (18%) patients with major 
PI RAMs. Of those, a substantial majority of 16 (89%) patients were receiving LPV/r as their bPI 
regimen, while two (11%) patients were receiving ATV (Table 2). The most common major PI RAMs 
observed were M46I and V82A (n = 12; 12%); I54V (n = 10; 10%); I84V and L76V (n = 7; 7%); 
I47A/V (n = 3; 3%); I50L/V (n = 2; 2%) and V32I (n = 2; 2%) (Table 1). 
InSTIs resistance-associated mutations 
In our cohort, we identified major InSTI RAMs in patients who had received the DRV containing 
regimen. One (1%) patient had a virus sequence with the Y143R major InSTI mutation in 
combination with the accessory T97A mutation, which confers high-level resistance to raltegravir 
(RAL), intermediate resistance to elvitegravir (EVG), and potential low-level resistance to bictegravir 
and dolutegravir (DTG). A patient receiving AZT, 3TC, EFV, d4T and LPV/r had a virus sequence 
with the T66I mutation (Table 3.1). The mutation identified and classified as an ‘accessory’ integrase, 
E157Q, occurred in two (2%) patients. One patient was receiving EFV, TDF and 3TC and the other 






In this study we analysed 96 HIV-1 sequences from PI-experienced and InSTI-naïve patients for 
major RAMs. The patients were being treated with a bPI second-line cART regimen and were 
suspected of virological failure. Second-line cART consisted of two NRTIs, backboned by a PI, if 
previously treated with an NNRTI-based regimen, and vice versa. 
As expected, major DRMs against NRTIs and NNRTIs were present at a rate of 65% (n = 65) and 
62% (n = 62), respectively. Despite being on a bPI, only 18% (n = 18) of our study sequences 
harboured major PI RAMs. This is in line with a previous study conducted in Sweden, where it was 
predicted that HIV-1 subtype C would be more prone to failure in bPIs 11. We identified 27 (27%) 
sequences not showing any DRM against the drug classes mentioned above and therefore could 
indicate a problem of poor adherence, rather than the selection of resistant variants.  
M184V, the most common NRTI RAM, occurred more frequently in patients receiving AZT plus 
3TC, in comparison with patients receiving the ABC plus 3TC regimen. Our findings correspond 
with previous studies conducted in South Africa with PLHIV, showing M184V/I as the most 
prevalent NRTI mutation 12–17 The K65R and Y115F RAMs occurred more frequently in patients 
receiving AZT plus 3TC, rather than in patients receiving ABC plus 3TC. TAMS 1 and 2 pathway 
mutations occurred more frequently in patients receiving the AZT plus 3TC cART regimen, but were 
low in patients receiving ABC plus 3TC, TDF plus 3TC, and FTC plus TDF. The most frequent TAM 
was K70R/E, which occurred mostly in patients receiving AZT plus 3TC, as opposed to ABC plus 
3TC and FTC plus TDF. In our study, M184V, L74V, K65R and Y115F were the most common 
major NRTI RAMs in patients receiving LPV/r as their bPIs.  
The K103N mutation occurred at a higher frequency in patients receiving AZT plus 3TC or ABC plus 
3TC than in those receiving TDF plus 3TC, and 3TC plus d4T. The high rate of K103N RAM is also 
well documented and has been observed in several previous studies15,19-19. The group receiving AZT 
plus 3TC or ABC plus 3TC showed the highest rates of NNRTI mutations such as P225H, V106M, 
E138A/G/K/Q, G190A/S, and Y188L occurred most frequently in patients receiving AZT plus 3TC 
or ABC plus 3TC.  
The majority of our patients were receiving LPV/r as their bPIs. The M46I and V82A RAMs were 
the most common mutations observed in patients receiving LPV/r compared with ATV. We identified 
a low frequency of M46I and V82A in patients receiving ATV as their bPIs. The group receiving 
AZT plus 3TC or ABC plus 3TC showed the highest rate of PIs such as I54V, I84V, L76V, I47A/V, 
I50L/V and V32I. Our findings are in agreement with Neogi et al., 13 study where major PI RAMs 




(10/43) and L90M 16% (7/43) were the most frequent. Our findings also shown M46I and V82A 
RAMs as the most prevalent major PI RAMs. Chimbetete et al. in 2018 observed similar results, with 
all three drug classes showing their DRMs at similar rates 20. The most common PI RAM reported by 
Chimbetete et al. was M46I 28 (33%), followed by I50V 18 (21%) and V82A 18 (21%). We observed 
more high-level resistance to patients receiving LPV/r compared with ATV and DRV. Van Zyl et 
al.’s 17 findings are consistent with ours, as they also identified more high-level resistance in patients 
receiving LPV/r compared with those receiving ARV and DRV. 
We analysed the integrase gene for the presence of treatment-compromising polymorphisms and 
DRMs against InSTIs. We observed the presence of Y143R in combination with T97A in one of our 
patient receiving ABC, 3TC, LPV/r. N155H, Q148H/R/K and Y143R/C/H are the three major 
recognised pathways of genotypic resistance against InSTIs 21. We confirmed Y143R in our study 
and this mutation in combination with T97A also impaired EVG susceptibility and showed possible 
low-level resistance. Furthermore, our data suggest that EVG activity is compromised in the presence 
of any RAL RAM, in this case Y143R. We also identified the presence of E157Q in 2 (2%) patients. 
The presence of this mutation is concerning, as these mutations are associated with potential low-
level resistance to both RAL and EVG. In a previous study conducted by Brado et al 22. We also 
found E157Q on HIV-1-infected South African sequences retrieved from the HIV database. Viruses 
having E157Q were found to be associated with treatment failure of a DTG-containing regimen 22 A 
study has shown that eight patients who had the E157Q mutation and were initiated with DTG-based 
therapy did not experience viremia suppression below detection level 23. 
Furthermore, we identified the presence of T66I mutation in 1 (1%) patient. T66I confers resistance 
mutation to low-level resistance to RAL and high-level resistance to EVG. The low prevalence of 
DRMs to InSTIs in our cohort should not be underestimated. RAMs against InSTI raises the question 
about the positioning of DTG in the treatment guidelines for South Africa. Previous studies have 
shown that a considerable minority of patients develop cross-resistance to DTG after exposure to 
RAL and EVG; resistance to DTG has not yet been reported in patients from South Africa 24,25. As 
DTG was proposed as the first-line drug, it is essential to conduct studies in real-life clinical settings 
to identify the efficacy of DTG with limited viral load monitoring and without drug resistance 
genotyping may compromise the roll-out of the InSTIs. 
Our study had some limitations that merit comments. First, the sample size was small compared to 
the total number of patients who are receiving cART in South Africa. It is unlikely to be a biased 
sample, however, because to the best of our knowledge there has not been any statistical study that 
reports on the number of patients receiving second-line cART from South Africa. Second, the 




cannot tell for certain whether the patients having RAL resistance according to the sequence have had 
access to an RAL-based treatment regimen. Fourth, we did not have any adherence data for these 
patients. To the best of our knowledge, this is the first study from South Africa to show the resistance 
pattern against InSTIs-based regimen patients on cART failure. Finally, the DRM data were only 
based on population sequencing, therefore we could not detect minor mutations below 20% of the 
population. 
In conclusion, we identified patterns of RAMs against reverse transcriptase inhibitors and PIs from 
patients suspected of failing on the South African second-line national cART programme. Very low 
or no primary InSTI RAMs were detected in second-line failure patients. The majority of them had 
M184V mutations that could have been carried over from the first-line cART. The non-identification 
of any RAMs in one-third of the patients and the presence of PI RAM in only one-fifth of the patients 
indicate that the failure may not be due to RAM, but might be due to adherence. Given the limited 
cART drug availability and high public health burden, we strongly propose for continued monitoring 
of RAMs in our setting. Data generated from this study can assist in the development of cART 
guidelines for patients who experience treatment failure in resource-limited setting where genotyping 
is not available. Studies that address operational issues, such as the optimal use of treatment 
monitoring tools, should be a research priority.  
Patients and methods 
Ethics statement 
The Health Research Ethics Committee of Stellenbosch University, South Africa (N15/08/071) 
approved the study. The study was conducted according to the ethical guidelines and principles of the 
Declaration of Helsinki 2013, the South African Guidelines for Good Clinical Practice and the 
Medical Research Council Ethical Guidelines for Research. The Health Research Ethics Committee 
of Stellenbosch University, South Africa awarded a waiver of a written informed consent to conduct 
sequence analyses on these samples. 
Study design 
HIV-1-positive patient samples were obtained randomly, without any knowledge of drug-resistance 
pattern, from the diagnostic section at the Division of Medical Virology, Stellenbosch University, 
and the South African National Health Laboratory Services (NHLS). Samples were collected between 
March 2017 and February 2018. Patients had their samples submitted for HIV-1 genotypic resistance 
testing to the NHLS. The NHLS provides routine genotypic antiretroviral drug resistance testing for 




We included samples from children (aged below 12 years) suspected of failing on bPI – which is used 
as first-line therapy in children – and adults suspected of experiencing virological failure on a bPI 
second-line cART regimen, for which treatment information, as provided by the physicians, was 
available. The treatment history was collected retrospectively. The selection consisted of plasma 
samples (n = 96) obtained from patients receiving second-line cART, according to the South African 
national cART guidelines 6. These patients are eligible for InSTI treatment consideration. 
Genotypic resistance testing 
We performed genotypic resistance testing using viral RNA extracted from plasma. The HIV-1 
protease and reverse transcriptase gene fragments were PCR-amplified using a slightly modified 
protocol as previously described by us 26. Briefly, HIV-1 protease and reverse transcriptase first-
round cDNA synthesis through reverse transcription was done using amplification primers HIV-PR 
outer 50prot1 (5’- TAA TTT TTT AGG GAA GAT CTG GCC TTC C -3’) and HIVRT outer Mj4 
(5’- CTG TTA GTG CTT TGG TTC CTC T –3’), position 2085-2109 and 3399-3420 of the HXB2 
reference numbering, with an expected fragment size of approximately 1314 base pairs (bps).27 For 
second-round PCR amplification, primers 50prot2 (5’- TCA GAG CAG ACC AGA GCC AAC AGC 
CCC A –3’) and NE13 (5’- CCT ACT AAC TTC TGT ATG TCA TTG ACA GTC CAG CT –3’), 
position 2136-2163 and 3334-3300 of the HXB2 reference numbering, with an expected fragment 
size of approximately 1300bps, were used 27. The integrase gene fragment amplification steps were 
performed as previously described by us 22. Sequencing reactions were performed as previously 
described by us 22. As part of quality control, each of the viral sequences were inferred on a 
phylogenetic tree in order to eliminate possible contamination. DRMs were interpreted using the 
Stanford University HIV Drug Resistance Database version 8.7 (https://hivdb.stanford.edu/).  
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4.4. Background 
High throughput sequencing has unique advantages and significantly improves the sensitivity in 
quantifying the minority HIV drug resistance (HIVDR) variants within the HIV quasispecies. 
Increased identification of pre-treatment minority drug resistance mutations (DRM) compared to 
Sanger based sequencing genotypic resistance testing (GRT) were reported from both resource rich 
as well as resource limited settings (RLS). This chapter evaluated the HIV-1 drug resistance 
associated mutations (RAMs) at the minor viral populations, by high throughput sequencing 
genotypic resistance testing (HTS-GRT), in patients suspected of failing on South African national 





4.5. Main findings 
HIV-1 subtyping identified 55 samples as HIV-1 subtype C and one as CRF02_AG. The major PI, 
NRTI, NNRTI and INI RAMs were observed 27% (15/56), 57% (32/56), 50% (28/56) and 7% (4/56) 
(Figure 4.1a). PI RAMs were observed in minor viral quasispecies (25%; 14/56), compared to NRTI 
(11%; 6/56), NNRTI (9%; 5/56) and INI RAM (4%; 2/56). 41% (23/56) did not have any PI RAMs. 
4.6. Study significance 
We have used high throughput sequencing to type the DRM in both minor (<20% of the population) 
and major (>20% of the population) viral quasispecies and identified increased PI RAM in minor 
viral populations. Our study also indicated low level of transmitted INI RAMs in patients failing on 
bPIs based regimen in South African PLHIV-1. 
4.7. Conclusion 
This study shows that use of high throughput resistance testing for GRT can greatly improve the 
identification of PI RAMs in bPI failing patients. Deep sequencing could be of greater value in 
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Introduction: HIV-1C have been shown to have a greater risk of virological failure towards boosted-
protease inhibitors (bPIs), a component of second-line combination antiretroviral therapy (cART) in 
South Africa. This study aimed at evaluating the HIV-1 drug resistance associated mutations (RAMs) 
at the minor viral populations, by high throughput sequencing genotypic resistance testing (HTS-
GRT), in patients suspected of failing on South African national second-line cART regimen with 
bPIs. 
Materials and methods: Plasma was obtained from 56 patients. The complete pol gene was 
amplified and sequenced with Illumina HiSeq2500, followed by bioinformatics analysis to quantify 
the RAMs according to the Stanford HIV drug resistance database.   
Results: PI RAMs statistically significant (p<0.001) were observed in minor viral quasispecies (25%; 
14/56), compared to nucleoside reverse transcriptase inhibitors (NRTIs) (11%; 6/56), non-nucleoside 
reverse transcriptase inhibitors NNRTIs (9%; 5/56) and integrase inhibitors (INIs) RAM (4%; 2/56). 
The majority of the DRMs in the minor viral quasispecies were observed in the V82A mutation 
(n=13) in protease, K65R (n=5), K103N (n=7) and M184V (n=5) in reverse transcriptase. 
Conclusion: HTS-GRT improved identification of PI and RTI RAMs in second-line cART patients 
from South Africa, compared to the conventional GRT with ≥20% used in Sanger-based sequencing. 
Several RTI RAMs like K65R, M184V or K103N and PI RAM V82A were identified in <20% 







High throughput sequencing has unique advantages and significantly improves the sensitivity in 
quantifying the minority HIV drug resistance (HIVDR) variants within the HIV quasispecies.1 
Increased identification of pre-treatment minority drug resistance mutations (DRM) compared to 
Sanger based sequencing genotypic resistance testing (GRT) were reported from both resource rich 
as well as resource limited settings (RLS).2, 3 However, the role of minority drug resistant variants 
and its clinical consequences in failure of combination antiretroviral therapy (cART) is debatable. 
Studies have shown that even in adherent patients, those with pre-existing Y181C mutants have a 
three times higher risk of virological failure on an efavirenz (EFV) based cART regimen.4 Several 
studies have shown that minority pre-treatment drug resistance was associated with reduced treatment 
efficacy.3, 5 In contradiction, other studies have indicated that in a population with a relatively low 
prevalence of DRM, the utility of deep sequencing to detect minority HIV-1 DRM have limited 
clinical benefit.6 A more recent study reported that incorporating the minor DRM might improve the 
predictive value of GRT, but very low thresholds of minority mutations can compromise the test 
specificity.7 Data on acquired minority mutations on treatment failure patients are limited. 
HIV-1 subtype C (HIV-1C) is the major HIV-1 subtype in South Africa, responsible for more than 
90% of infections. The recommended second-line cART consists of the nucleoside reverse 
transcriptase inhibitors (NRTIs) zidovudine (AZT) or tenofovir (TDF) and lamivudine (3TC) and a 
ritonavir-boosted (/r) protease inhibitor (PI), usually lopinavir (LPV/r).8 Our earlier study from 
Sweden reported that despite good adherence there is an increased risk of virological failure in 
patients with HIV-1C, on bPI-based regimens.9 The ex vivo and in vitro experiments also indicated 
large variation in susceptibility of HIV-1C viruses in absence of PI resistance associated mutations 
(RAMs).10 
Studies have reported that the rates of virological failure on second-line cART are high in resource-
limited settings, including South Africa and associated with duration of exposure to previous drug 
regimens and poor adherence,11 mostly without any protease RAM.12 In South Africa, with more than 
4.5 million HIV-infected individuals accessing cART, with about 145,000 (∼4%) accessing second-
line cART.13 However, the drug resistance pattern in patients failing on bPIs are limited and often 
described by GRT by Sanger Sequencing.14 An earlier study with only seven patients indicated the 
presence of PI RAMs in bPI failure patients, which was missed by bulk Sanger sequencing.15 
Therefore, the primary aim of the present study is to find the level and pattern of HIVDR in minor 





Material and Methods: 
Patient material: Plasma samples were obtained from bPI suspected of failing patients’ (as referred 
by the clinician) from the diagnostic section at the Division of Medical Virology, Stellenbosch 
University, and the South African National Health Laboratory Services (NHLS) that were collected 
between March 2017 and February 2018. Viral RNA was extracted using the Viral RNA Extraction 
kit (Qiagen, GMBH) and stored in -80OC. The study was approved by the Health Research Ethics 
Committee of Stellenbosch University, South Africa (N15/08/071). 
PCR amplification and high throughput sequencing: 
Reverse transcriptase PCR (RT-PCR), which consists of cDNA synthesis followed by first round 
PCR, were performed using the SuperScript™ III One-Step RT-PCR System with 
Platinum™ Taq DNA Polymerase (Invitrogen/Life Technology, Cat No. 12574026) using the 
primers 1810F (5’-GCTACACTAGAAGAAATGATGACAGCATG-3’) and 5220R (5’-
CCCTAGTGGGATGTGTACTTCTGA-3’). The second round nested PCR was performed with 
2001F (5’-TGCAGGGCCCCTAGGAAAAAGGGCTGTT-3’) and 5087R (5’- 
ATCCTGTCTACYTGCCACACAAYC-3’) primers using KAPA HiFi HotStart ReadyMix PCR kit. 
The amplified products were purified using the QIAamp gel extraction kit (Qiagen, Germany). For 
HTS, the purified amplicons were fragmented, and the library was prepared using NEBNext® Ultra™ 
DNA Library Prep Kit for Illumina® (New England Biolab, USA) with multiplexed NEB next 
adaptors. The samples were then pooled together with other unrelated non-viral indexed libraries. 
Paired end sequences of read length 250 bp were carried out on the Illumina HiSeq2500. The 
sequences are available in SRA (Submission ID : SUB5871663). 
Bioinformatics analysis:  
The raw reads were adapter trimmed using TrimGalore version 0.6.2, followed by the removal of the 
low-quality bases (phred value score <Q30) by Sickle version 1.33. Duplicate reads were removed 
using FastUniq. The de novo assembly was performed using the Iterative Virus Assembler (IVA). 
The processed reads were aligned against individual pol gene sequence in very sensitive local mode 
using Bowtie2, in order to select reads originated from pol gene and create a consensus gene. The 
subtyping was performed using REGA version 3. The selected reads were then aligned against Pol 
protein sequences using the blastx program from BLAST package. Best blastx hit was chosen for 
each read for the amino acid counting which was performed by in-house script. The resistance was 
interpreted as per the mutation lists provided in Stanford University HIV Drug Resistance Database, 






Among the 67 samples sequenced, current treatment regimen data were not available for 11 samples, 
thus they were excluded from further analyses. Among the 56 patients 5.3% (n=3) were on boosted 
ATV, while only one patient was on DRV and the rest 93% (n=52) were receiving LPV/r. The median 
(range) viral load was 71814 (937-5500000) RNA copies/mL. HIV-1 subtyping identified 55 samples 
as HIV-1 subtype C and one as CRF02_AG. The major PI, NRTI, NNRTI and INI RAMs were 
observed 27% (15/56), 57% (32/56), 50% (28/56) and 7% (4/56) (Figure 1a). Statistically significant 
(p<0.001) higher PI RAMs were observed in minor viral quasispecies (25%; 14/56), compared to 
NRTI (11%; 6/56), NNRTI (9%; 5/56) and INI RAM (4%; 2/56). 41% (23/56) did not have any PI 
RAMs. The complete mutation profile is presented in supplementary table 1. There is no statistical 
difference in viral load (log10 copies/mL) in patients who only had PI DRM in minor population 
variants, compared to patients who had only DRM in the major viral population [Mean (SD): 4.92 
(0.74) vs 4.66 (0.88); p=0.43]. All 56 patients harbored at least one DRM. Most of the DRM in the 
minor viral quasispecies were observed in V82A mutation (n=13) in protease, K65R (n=5), K103N 
(n=7) and M184V (n=5) in reverse transcriptase (Figure 1b). Despite no mention of use of any INIs 
by the clinical reports, three patient sequences had the Y143R mutation in major viral quasispecies 
and one in minor viral quasispecies, which confers resistance to raltegravir (RAL). However, 
resistance to INI inhibitors were low in the settings. The predicted resistance pattern (as per the 
Stanford HIVDB) was given in Figure 1c. Half (28/56) of the patients had doravirine cross-resistance. 
There were two patients (ZA94 and ZA97) who are resistant to all classes of drugs indicates the 





Figure 4.1. Percentage prevalence, number of different RAMs and predicted level of resistance 
(a) Percentage prevalence of PI, NRTI, NNRTI and INI RAMs in minor (<20% of the populations) 
and major (≥20% of the populations) viral populations alone and together. The RAM in minor viral 
quasispecies are indicated. (b) Number of different RAMs in minor (<20% of the populations) and 
major (≥20% of the populations) viral populations (c) Predicted level of resistance to different 
antiretroviral drugs based on Stanford HIV database. 
Discussion:  
In this study we have used high throughput sequencing to type the DRM in both minor (<20% of the 
population) and major (>20% of the population) viral quasispecies and identified increased PI RAM 
in minor viral populations. Our study also indicated very lower level of transmitted INI RAMs in 
patients failing on bPIs based regimen. 
Earlier studies have indicated that PI RAMs were uncommon in patients failing on second line cART, 
with only 7% patients on bPIs showing PI RAMs.17 A recent report using Sanger Sequencing, 
indicates that 35% of the patients had PI DRMs failed on bPIs.18 Our study also showed that 34% of 




DRM in the minor viral population. All the patients had at least one DRM. As most of the patients 
had high viral loads, there is a high chance of transmission of DRM if not treated timely. Furthermore, 
the PI RAMs in minor viral population can evolve to become majority under drug selection pressure. 
Earlier studies indicated that HIV-1C has reduced susceptibility towards the PIs without emergence 
of major PI RAM 19 and there is higher risk of virological failure.9 Gag mutations can also confer 
reduced susceptibility towards PIs.20 Clinical studies also reported that the second line failure was 
frequent in South African settings,14 this could further increase chance of transmission of primary 
DRMs. 
 
Even though there is no indication of the patients being administered RAL, three of the patients in 
our study harbored Y143R mutation in >20% of the population. Previous studies in HIV-1C have 
shown major INI mutations at baseline in less than 5% of the patients from Ethiopia (T66I, E138K, 
Q148R, and Q148H) and South Africa (Q148H, T66S, E92G, S147G, T66A, Y143YF and Y143H). 
3,12 However, presence of INI RAMs in minor viral populations are deemed not have any clinical 
consequences.21 
In conclusion, this study shows that use of high throughput resistance testing for GRT can greatly 
improve the identification of PI RAMs in bPI failing patients. Using HTS-GRT, PI RAMs (V82A) 
and RTI RAMs (K65R, M184V or K103N) were identified in <20% population that Sanger-based 
sequencing failed to identify strengthening their role in detecting the acquired mutations early.  
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experiments (Viral RNA extractions, PCRs, Sanger sequencing and initial sequence analyses) for the 
Tygerberg Virology (TV) samples.  I confirmed the sequences information (patient’s demographics, 
raw data and aligned sequences) for further analyses to Prof. Kamalendra Singh. Prof Singh and I 
were both in frequent communication regarding the Integrase polymorphism structural analyses in 
the context of South African HIV-1C. 
5.4. Background 
Integrase (IN) integrates viral DNA into the host genome using its 3'-end processing and strand-
transfer activities. As InSTIs are becoming increasingly accessible worldwide, it is important to 
understand the mechanism(s) of InSTI susceptibility. There is strong evidence suggesting differences 
in the patterns and mechanisms of drug resistance between HIV-1 subtype B, which dominates in 
United States, Western Europe and Australia, and non-B infections that are most prevalent in 
countries of Africa and Asia. Polymorphisms (PM) are defined as the change in genomic sequence 
variation that is common in more than 1% of the sequences. IN PM and other genetic differences 
among diverse subtypes are likely responsible for these different patterns, but lack of a full-length 
high-resolution structure of HIV-1 IN has been a roadblock in understanding the molecular 
mechanisms of InSTI resistance and the impact of polymorphisms on therapy outcome. Here we use 
molecular modelling to explore the structural impact of IN polymorphisms on the IN reaction 




5.5. Main findings 
Among all non-B subtype sequences, 17 naturally occurring IN PM positions with 18 PMs were 
observed. Three of these (K14R, D25E, and V31I) belong to the N-terminal domain (NTD), whereas 
M50I belongs to the loop region connecting the NTD and C-terminal domain (CTD). Eight PMs 
(I72V, L74M/I, F100Y, L101I, T124A, K136Q, and D167E) are part of the catalytic core domain 
(CCD), and the remaining six (V201I, T218I, L234I, A265V, R269K, and S283G) belong to the CTD. 
Eight PMs (I72V, L74M/I, F100Y, L101I, T124A, K136Q, and D167E) are part of the CCD, and the 
remaining six (V201I, T218I, L234I, A265V, R269K, and S283G) belong to the CTD. The other two 
were in regions for which structural data are unavailable. IN PM T218I lies within the missing region 
(residues 205–222).  
5.6. Study significance 
We have presented extensive analyses of IN PMs in the structural context. This structure provides the 
first glimpse of nucleoprotein organisation, which could be used to deduce the effect of a PM. Our 
analyses suggest that there are several naturally occurring polymorphisms that may affect the 
structural stabilities of the IN, vDNA binding, and drug binding propensity. The cryoEM structure of 
the HIV-1 strand transfer complex (STC) is a milestone in the structural biology of integrase. To 
elucidate the IN structural aspects, this study model the IN nucleoprotein complexes from different 
subtypes in combination with sequence analyses.  
5.7. Conclusion 
In this study, we conducted deep analyses with the IN Polymorphisms (PMs) and our data shows how 
these natural occurring PMs may affect the structural stabilities of the IN and vDNA binding. 
Furthermore, data generated from this study can provide necessary guidance for investigating natural 
occurring polymorphisms. 
5.8. Open access  
The article is open access and freely available online. Reprints can also be obtained from the author 











































Chapter 6 Molecular dynamic simulations to investigate the structural 
impact of known drug resistance mutations on HIV-1C Integrase-
Dolutegravir binding 
6.1. Article title  
Molecular dynamic simulations to investigate the structural impact of known drug resistance 
mutations on HIV-1C Integrase-Dolutegravir binding. 
6.2. Authors and citations 
Rumbidzai Chitongo1*¶, Adetayo Emmanuel Obasa2*¶, Sello Given Mikasi2, Graeme Brendon 
Jacobs2, Ruben Cloete1¶ 
Citation number: none 
6.3. Author’s contribution 
In the enclosed manuscript; I confirmed that I am a joint-first author. I obtained the patient samples, 
performed the laboratory experiments, including Viral RNA extraction, PCR, PCR clean-up reactions 
and conventional Sanger sequencing. I obtained additional sequences from theHIV Los Alamos 
National Library Database (www.lanl.gov). I performed the sequence analyses, sent the aligned and 
consensus sequences for In-silico simulation to Dr. Ruben Cloete and Miss Rumbidzai Chitongo. I 
had in person weekly meetings with Dr. Cloete, discussing and analysing the data. 
6.4. Background 
Resistance associated mutations (RAMs) threaten the long-term success of combination antiretroviral 
therapy (cART) outcomes for HIV-1 treatment. HIV-1 Integrase (IN) strand transfer inhibitors 
(INSTIs) have proven to be a viable option for highly specific HIV-1 therapy. The INSTI, 
Dolutegravir is recommended by the World Health Organization for use as first-line cART. This 
study aims to understand how RAMs affect the stability of IN, as well as the binding of the drug onto 
the catalytic pocket of the protein. Computational methods have been used to assess the impact of 
known RAMs on the binding of Dolutegravir to the IN protein. Molecular modelling of HIV-1C IN 
was performed using the SWISS-MODEL webserver, with quality assessment performed using 
internal methods and external software tools. The site directed mutator webserver was applied for 




6.5. Main findings 
All the MD trajectory analysis considered the single chain A (monomer) of the IN protein in contact 
with the drug DTG. Trajectory analysis of the root mean square deviation (RMSD) of the backbone 
indicated that the WT system reached equilibrium after 100 ns as well as the Q92, R143 and S140 
mutant systems. We performed interaction analysis for five snapshots (every 50 ns) of each of the 
simulation systems to determine which residues played a role in the binding of DTG to the protein in 
the WT and mutant protein structures. For the WT system, interactions were observed between known 
active site residues D64, D116 and N148, MG ion and to DNA nucleotides  
6.6. Study significance 
Our findings suggest the G140S mutant has a strong effect on the HIV-1C IN protein structure and 
Dolutegravir binding and should be validated using laboratory-based experiments. This approach can 
be applied to determine the effect of other mutations/variants on HIV-1C integrase drug binding. 
6.7. Conclusion 
The findings from our study suggest that patients should be screened for mutations and or novel 
variants to determine if the drug DTG will be efficacious or not. The model generated in this study 
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Resistance associated mutations (RAMs) threaten the long-term success of combination antiretroviral 
therapy (cART) outcomes for HIV-1 treatment. HIV-1 Integrase (IN) strand transfer inhibitors 
(INSTIs) have proven to be a viable option for highly specific HIV-1 therapy. The INSTI, 
Dolutegravir is recommended by the World Health Organization for use as first-line cART. This 
study aims to understand how RAMs affect the stability of IN, as well as the binding of the drug onto 
the catalytic pocket of the protein. Computational methods have been used to assess the impact of 
known RAMs on the binding of Dolutegravir to the IN protein. Molecular modelling of HIV-1C IN 
was performed using the SWISS-MODEL webserver, with quality assessment performed using 
internal methods and external software tools. The site directed mutator webserver was applied for 
stability predictions on the effect of known RAMs while FoldX confirmed any changes in energy. 
Interaction analysis between neighbouring residues was done using PyMOL. Three randomly selected 
mutations were chosen for molecular dynamic simulation studies using Gromacs. Trajectory analysis 
included Root mean square deviation and fluctuation, Radius of gyration, Principal component 
analysis and Interaction analysis between Dolutegravir and protein residues. The structural quality 
assessment indicated high reliability of the HIV-1C IN tetrameric structure, with more than 90% 
confidence in modelled regions. Change in free energy for the G140S mutant indicated a stabilizing 
effect and simulation analysis showed it to affect structural stability and flexibility of the protein 
structure. This was further supported by the drug being expelled from the G140S mutant active site, 
as indicated by interaction analysis. Our findings suggest the G140S mutant has a strong effect on the 
HIV-1C IN protein structure and Dolutegravir binding and should be validated using laboratory-based 
experiments. This approach can be applied to determine the effect of other mutations/variants on 






The Integrase (IN) enzyme plays an important role in the Human Immunodeficiency Virus type 1 
(HIV-1) replication cycle by catalysing two distinct reactions termed: 3'-end processing and strand 
transfer. During the 3' processing, IN removes two nucleotides from the 3' ends of both viral DNA 
strands and exposes the C-alpha hydroxyl group on the 3'ends. The subsequent step involves strand 
transfer whereby, IN attacks the phosphodiester backbone of the host DNA and links the exposed 3'-
end to the 5' hydroxyl end of the host DNA [1]. This makes HIV-1 IN an important target for 
combination antiretroviral therapy (cART). HIV-1 IN is a 32 kilo Dalton (kDa) protein, and consist 
of three structural and functional domains; the N-terminal domain (NTD, residues 1-49), the catalytic 
core domain (CCD, residues 50-212), and C-terminal domain (CTD, residues 213-288). It also 
contains a conserved DDE motif consisting of residues Asp54, Asp116 and Glu152 in the CCD, 
important for drug binding and enzyme activity [2]. Several IN strand transfer inhibitors (INSTIs) 
have been developed [3–5]. These inhibitors include; Raltegravir (RAL) and Elvitegravir (EVG) as 
first-line INSTIs and the most recently approved second-line inhibitors Dolutegravir (DTG) and 
Bictegravir (BIC) [6].  
DTG is a coplanar and linear molecule with a high barrier against resistance, it is safe and tolerable 
and shows little to none drug interactions [7]. Furthermore, a recent study provided evidence for the 
replacement of RAL with DTG based on the low prevalence of DTG resistance and the low risk for 
INSTI mutations when patients are on DTG treatment [8]. Although BIC has been recently approved, 
not much information is known about it and as a result, DTG still remains the preferred option. The 
functional mechanism of INSTIs is to bind to the catalytically essential magnesium ions, thereby 
displacing the reactive 3'-hydroxyl group of the terminal A17 away from the active site which disrupts 
the strand transfer process. Several mutations have emerged in patients receiving first-line INSTIs, 
RAL and EVG. Brado et al.  reported that despite higher fold RAMs against INSTIs being absent in 
most treatment naïve patients, they can emerge under treatment, particularly with first generation IN
STIs [9].  
Several studies have used the prototype foamy virus intasome structure (medium sequence identity) 
to model the structure of HIV-1 IN in order to investigate the effect of mutations on HIV-1 IN using 
molecular dynamic simulations [10]. These studies revealed the binding mode of EVG and RAL to 
HIV-1 IN and the structural mechanism of drug resistant mutants that affect the 140's loop region 
spanning residues 140-149. The precise role of this loop is unknown, but molecular dynamics studies 
have demonstrated the importance of this loop’s flexibility for catalysis [11]. This loop has been 
reported to regulate the active site of HIV-1 IN by decreasing or increasing flexibility under the 




important for the catalytic steps following DNA binding, as a decrease in flexibility induced, for 
example, by the G140A mutation, results in lower levels of activity, despite minimal effects on DNA 
binding [11]. Mouscadet et al. [12] reported that the G140 residue is not directly involved in the 
cooperative flexibility of the catalytic loop, but plays a critical role in controlling the overall motion 
of the loop and its precise position relative to the phosphodiester bond to be cleaved. The G140 
residue also participates in the catalytic loop hinge formation and its mutation may restore specific 
contacts required for catalysis, between the loop of the double mutant and the end of the viral DNA 
[11,13,14].  The findings from these studies were inconclusive due to the poor quality of the protein 
models delineating the active site and viral DNA binding site for simulation studies.  
In 2017, Cryogenic electron microscopy was used to solve the structure of HIV-1 strand transfer 
complex intasome for HIV-1 subtype B [15]. This provided us with a unique opportunity to model 
the structure of HIV-1 subtype C IN to interrogate the effect of known drug resistance associated 
mutations (RAMs) on the protein structure using molecular dynamic simulation studies. This is the 
first study that uses the consensus wild type subtype C IN sequence to build an accurate 3D model of 
HIV-1C IN to understand the effect of three statistically enriched mutations on DTG drug binding.  
Materials and Methods 
Generation of consensus HIV-1C Integrase sequence 
To compare our sequences with the rest of the IN sequences from South Africa, we performed a 
search on the HIV Los Alamos National Library (LANL) database (https://www.hiv.lanl.gov/comp
onents/sequence/HIVsearch.com). Our search inclusion criteria included all South African HIV-1 
subtype C IN sequences and those identified from treatment naïve patients. We selected one sequence 
per patient and all problematic sequences were excluded from further analyses. Finally, the consensus 
sequence was generated using the database-derived HIV-1CZA sequences (n = 314) and cohort 
sequences (n = 91) [9] . Nucleotide sequences were verified for stop codons, insertion and deletions 
using an online quality control program on the HIVLANL database 
(https://www.hiv.lanl.gov/content/sequence/QC/index.htm). Multiple sequence alignments were 
done with MAFFT version 7, from which the consensus sequence was derived [16]. As part of quality 






Molecular modelling and quality assessment 
The crystal structure of the HIV-1B intasome (PDBID: 5U1C) was used to generate a three-
dimensional tetrameric structure of HIV-1C IN using the consensus HIV-1C sequence that we 
generated. The SWISSMODEL webserver was used for model generation by first constructing a 
pairwise sequence-structure alignment between HIV-1C wild-type (WT) amino acid sequence and 
template 5U1C [17]. The quality of the resulting model was assessed using SWISSMODEL quality 
assessment scores, Root mean square deviation analysis compared to homologous template (PDBID: 
5U1C) and with publicly available algorithms located at the SAVES webserver 
(https://servicesn.mbi.ucla.edu/SAVES/) namely; ERRAT, VERIFY3D and Ramachandran plot 
[18,19]. 
Structure preparation 
The predicted 3D structure of HIV-1C IN was superimposed to 5U1C to extract proviral DNA, while 
the Magnesium (MG) ions and drug DTG were obtained from homologous template 3s3m (Prototype 
foamy virus). The wild-type (WT) structure of HIV-1C was energy minimized in complex with DNA, 
MG and DTG using Gromacs version 5.1 [20]. Thereafter, we predicted the stabilizing and/or 
destabilizing effect of mutations on the protein structure. For this purpose, the site directed mutator 
(SDM) webserver and the software FoldX was used to predict the change in Gibbs free energy after 
the introduction of the mutation. We also calculated the loss or gain of polar interactions between 
neighbouring residues located adjacent to the mutation using PyMOL [21]. 
Molecular dynamic simulation  
For simulation studies we only considered the two inner dimers of the protein structure, as the other 
two monomers were similar in sequence and structure. Three different mutant systems were prepared 
by introducing a specific mutation into the WT structure through the mutagenesis wizard in PyMOL 
and energy minimizing the structures using Gromacs [20].  The WT and three mutant systems (E92Q, 
S140 and R143) were prepared by uploading the atomic coordinates of the Protein-DNA-MG-DTG 
complexes to CHARMM-GUI interface [22]. The three mutant systems selected for simulation 
studies represent three resistance pathways associated with RAL, EVG and possibly DTG resistance. 
The option solution builder was used as an input generator. Each system was solvated in a rectangular 
TIP3 water-box with 10Å distance between the edges of the box. The topology and coordinates for 
each system was generated using CHARMM36 force field and CHARMM general force field for 
DTG. Each system was neutralized by adding counter ions to each of the systems. For the WT system, 
157 potassium ions (K) and 81 chloride ions (Cl) were added, for the mutant R143 system we added 




mutant system Q92 we added 335 K and 276 Cl ions. Each system was at a final concentration of 
0.15M for simulation dynamics. 
Gromacs version 5.1 was used for running all the simulations [20]. Each system underwent 50000 
steps of steepest descents energy minimization to remove steric overlap. Afterwards, all the systems 
were subjected to a short position restraint NPT (constant Number of particles, Pressure and 
Temperature) for 500 picoseconds (ps) to stabilize the pressure of the system by relaxing the system 
and keeping the protein restrained. For NPT, the Nose-Hoover pressure coupling was turned on with 
constant coupling of 1ps at 303.15K under conditions of position restraints (h-bonds) selecting a 
random seed. Electrostatic forces were calculated using Particle Mesh Ewald method [20]. All 
systems were subjected to a full 300 ns simulation under conditions of no restraints. 
The analyses of the trajectory files were done using GROMACS utilities. The root mean square 
deviation (RMSD) was calculated using gmx rmsd and root mean square fluctuation (RMSF) analysis 
using gmx rms. The radius of gyration was calculated using gmx gyrate to determine if the system 
reached convergence over the 300 nanoseconds (ns) simulation. Pairwise distance analysis between 
the drug and MG was done using gmx pairdist tool. Afterwards we extracted structures every 50 ns 
over the last 200 ns of the equilibrated system to determine any structural changes and differences in 
the number of interactions between the protein and drug at different time intervals. 
Principal component analysis  
Principal component analysis (PCA) is a statistical technique that reduces the complexity of a data 
set in order to extract biologically relevant movements of protein domains from irrelevant localized 
motions of atoms. For PCA analysis the translational and rotational movements were removed from 
the system using gmx covar from GROMACS to construct a covariance matrix. Next the eigenvectors 
and eigenvalues were calculated by diagonalizing the matrix. The eigenvectors that correspond to the 
largest eigenvalues are called "principal components", as they represent the largest-amplitude 
collective motions. We filtered the original trajectory and project out the part along the most important 
eigenvectors namely: vector 1 and 2 using gmx anaeig from GROMACS utilities. Furthermore, we 
visualized the sampled conformations in the subspace along the first two eigenvectors using gmx 






Sequence and structural analysis 
The amino acid sequence of HIV-1C IN shared 93.4% sequence identity with the template 5u1c amino 
acid sequence. The protein structure built for HIV-1C IN had a Global mean quality estimate score 
of 0.59 and 60% sequence similarity to 5u1c. The tetrameric structure of HIV-1C is shown in Fig 1, 
with each monomer labelled and colour coded. The VERIFY 3D score was 80.1%, the ERRAT 
overall quality score was 90% and higher for all four chains (A, B, C and D) and the Ramachandran 
plot indicated more than 90% of residues fell within the most favoured regions of the plot suggesting 
the predicted structure is a reliable model. Stability predictions indicated 15 RAMs to be destabilizing 
and five to be stabilizing for the protein structure based on SDM delta-delta G free energy scores 
(Table 1). The FoldX change in unfolded energy values indicated that the S140 was stabilizing, Q92 
destabilizing and R143 neutral based on comparison with the WT structure each having values of 
162.89, 131.94, 146.47 and 151.83 Kcal/Mol, respectively. Interaction analysis showed ten mutations 
resulted in a loss of polar contacts; three resulted in an increase in polar contacts, while seven showed 
no change in the number of polar contacts with neighbouring residues (Table 1).  
 
Figure 6.1 Tetrameric 3D structure of HIV-1C Integrase in complex with DNA, MG and drug 
Dolutegravir. Magnesium2+ ions (dirty violet spheres) are shown sitting in close proximity with 
Dolutegravir (brown) within the binding pocket (DDE motif) of the protein. A pair of dimers is seen 
encapsulating the viral/host DNA chimera, in which the two inner molecules (chain A and C) are 




Table 6:1 Summary of stability predictions and polar interactions. 
 
 
SDM1 FoldX2 Polar Interactions 




Wild Type Mutant 
WT N.A 151.83 N.A N.A N.A 
T66A -1.2 
 
152.69 0.86 3 (H67, I73, ADE21) 1 (I73) 
T66I 0.08 
 
153.63 1.80 3 (H67, I73, ADE21) 1 (I73) 
T66K -0.61 
 
160.15 8.32 3 (H67, I73, ADE21) 1 (I73) 
E92Q -0.16 
 
131.94 -19.89 3 (Q136, I113, T115) 0 
E138K -0.12 
 
151.32 -0.51 3 (Q136, I113, T115) 2 (T115, I113) 
E138A -0.4 
 
152.01 0.18 3 (Q136, I113, T115) 2 (T115, I113) 
E138T 0.48 
 
151.82 -0.01 3 (Q136, I113, T115) 2 (T115, I113) 
G140S -0.58 
 
162.89 11.06 2 (T115, N117) 3 (Q148, T115, N117) 
G140A -0.68 
 
152.43 0.60 2 (T115, N117) 2(T115, N117) 
G140C 0.39 
 








152.49 0.66 None None 
Y143R -0.08 
 
146.47 -5.36 None 1 (S230) 
Y143H -0.07 
 
152.28 0.45 None None 
S147G -0.18 
 
151.16 -0.67 2 (Q148, N144) 1 (Q144) 
Q148H 0.63 
 
157.78 5.95 3 (V151, P145, S147) 2 (V151, P145) 
Q148K -0.78 
 
151.33 -0.50 3 (V151, P145, S147) 3 (V151, P145, H114) 
Q148R -0.71 
 




151.58 -0.25 3 (V151, P145, S147) 3 (V151, P145, H114) 
N155H -0.23 
 
152.01 0.18 3 (V151, P145, S147) 3 (E152, V151,  K159) 
R263K -0.29 
 
151.15 -0.68 4 (Q146, N144, GUA18, 
ADE18) 
0 
1negative values for ΔΔG indicate a stabilizing effect and positive values destabilizing. 
2positive energy difference ΔG values >1 indicate a destabilizing effect, whereas values 1 ≤ ΔG ≤ 0 imply a neutral effect and ΔG values > -1 indicate a 
stabilizing effect. Abbreviations used: N.A- not applicable. The number in front of brackets is the total amount of interactions. Abbreviations of amino 
acids: A -Alanine; D-Aspartic acid; E-Glutamic acid; G-Glycine; H-Histidine; I-Isoleucine; K-Lysine; N-Asparagine; Q-Glutamine; R-Arginine; S-





Molecular dynamic simulations 
All the MD trajectory analysis considered the single chain A (monomer) of the IN protein in 
contact with the drug DTG. Trajectory analysis of the RMSD of the backbone indicated that 
the WT system reached equilibrium after 100 ns as well as the Q92, R143 and S140 mutant 
systems (Fig 2A). Only S140 showed higher RMSD fluctuation values compared to the WT, 
R143 and Q92 systems (Fig 2A). RMSF analysis clearly showed higher flexibility for the S140 
mutant system, with four highly flexible regions (residues 68 - 70, 142 - 146, 166 - 170 and 253 
- 256) compared to the WT, Q92 and R143 systems (Fig 2B). These flexible regions affect the 
140’s loop region that regulates drug binding. The Radius of gyration values indicated 
decreasing values for R143 and E92 compared to the WT and S140 mutant system (Fig 2C). 
Plotting the first two principal components provided insight into the collective movement of 
each protein atom. The 2D projections of the first and second principal components for the WT, 
Q92, R143 and S140 systems are shown in Figure 2D. Calculation of the covariance matrix 
values after diagonalization showed a significant increase for the S140 system (18.33 nm) 
compared to the other three systems WT, Q92 and R143 each having 9.58 nm, 8.98 nm and 
10.41 nm lower values, respectively. Distance analysis indicated a smaller average distance of 
0.21   0.01 nm and 0.22   0.01 nm between the WT, R143 MG ion and drug DTG systems 
compared to Q92 and S140 each having a distance of 0.41   0.04 nm, 0.99   0.20 nm, 





Figure 6.2 Trajectory analysis of the four simulation systems.  
(A) Change in backbone RMSD for the WT, Q92, S140 and R143 systems plotted over 300 ns. 
(B) Change in RMSF for the C-alpha residues for the WT, Q92, S140 and R143 systems plotted 
over the last 200ns. (C) Measure of compactness for the WT, Q92, S140 and R143 systems 
plotted over the last 200 ns. (D) First two principal components plotted for the WT, Q92, S140 
and R143 systems plotted over the last 200 ns. 
Interaction analysis 
We performed interaction analysis for five snapshots (every 50 ns) of each of the simulation 
systems to determine which residues played a role in the binding of DTG to the protein in the 
WT and mutant protein structures. For the WT system, interactions were observed between 
known active site residues D64, D116 and N148, MG ion and also to DNA nucleotides (Table 
2). Similarly, interactions were observed between known active site residues D64, R143, N148, 
MG ion and DNA nucleotides for the R143 system (Table 2). Interestingly, no active site 
residue interactions between DTG and S140 structure was observed and no MG ionic 
interactions for S140. Only the Q92 system showed interactions with active site residues but no 
MG ionic interactions (Table 2). Figs A-D in S1 Supporting Information File shows the relative 
location of the drug to the MG ion and active site for snapshot 1 taken at 100 ns. Compared to 
the WT, R143, Q92 the drug DTG is located close to the MG ion and active site while for S140 
the drug is located outside the catalytic site suggesting the mutation is able to expel the drug 




Table 6:2 Summary of interaction analysis. 
Structure Cluster Interactions 
Hydrogen bonds Ionic 
WT 1 (100 ns) 2 (GUA22 D116) MG 
 2 (150 ns) 3 (THY11, D64, D116) MG 
 3 (200 ns) 2 (GUA22, D116) MG 
 4 (250 ns) 4 (THY11, GUA22, D64, D116) MG 
 5 (300 ns) 2 (THY11, N148) MG 
R143 1 (100 ns) 4 (THY11, GUA22, D64, N148) MG 
 2 (150 ns) 4 (GUA22, D64, R143, N148) MG 
 3 (200 ns) 4 (GUA22, D64, R143, N148) MG 
 4 (250 ns) 4 (GUA22, D64, R143, N148) MG 
 5 (300 ns) 5 (THY11; GUA22, GUA22, D64, N148) MG 
Q92 1 (100 ns) 3 (CYT20, D116, P145) None 
 2 (150 ns) 3 (D116, P145, E152) None 
 3 (200 ns) 3 (CYT20, H21, D116) None 
 4 (250 ns) 4 (CYT20, P142, P145, E152) None 
 5 (300 ns) 3 (CYT20, P145, N148) None 
S140 1 (100 ns) 3 (GUA22, ADE25, ADE27) None 
 2 (150 ns) 3 (GUA22, ADE25, ADE27) None 
 3 (200 ns) 3 (GUA22, ADE25, ADE27) None 
 4 (250 ns) 3 (THY11, GUA22, ADE27) None 






Sequence variation between HIV-1B and HIV-1C can have a meaningful contribution to the 
protein structure, affecting protein drug interaction. We investigated known drug RAMs 
associated with RAL, EVG and DTG resistance to determine their effect on the protein structure 
and drug binding. The structural modelling of HIV-1C IN considered a homologous template 
of high sequence identity, and good overall target sequence coverage, compared to previous 
homology models that considered templates of low sequence identity. We could therefore 
accurately reconstruct HIV-1C using the close homolog HIV-1B crystal structure as template 
to infer accurate drug interactions. Further inspection of the overall structure confirmed 
accurate prediction of more than 90% of domains within the protein structure, compared to the 
template HIV-1B structure. The quality analysis provided support for the predicted model based 
on side chain conformations. Stability predictions showed contrasting results to interaction 
analysis, whereby amino acid substitutions that resulted in a gain of interactions was predicted 
to be destabilising. The FoldX changes in energy values were similar to interaction analysis for 
the three mutant structures under investigation. To fully comprehend the effects of individual 
mutations we opted to use molecular dynamic (MD) simulations to understand the effect of 
selected mutations on protein movement and drug interactions. MD analyses have shown to be 
successful in quantifying small changes in protein structures that can affect overall drug binding 
[23]. We randomly selected three mutations Q92, S140 and R143 to investigate the role of 
amino acid substitutions on protein structure and drug binding in comparison to the WT protein 
structure. Analysis of the change in trajectory of the mutant systems compared to the wild type 
suggested less stability and higher fluctuation of the G140S mutant system compared to the WT 
system. We also confirmed the destabilizing effect of the G140S mutant using principal 
component analysis which suggested larger randomized concerted movement for the G140S 
mutant compared to the WT, Q92 and R143 systems.  
These findings are similar to Chen et al. [10] which showed that the G140S mutations can either 
stabilize or destabilize the 140’s loop region. In our case, the 140’s loop region is stabilized by 
the G140S mutation that could prevent drug binding. This is supported by pairwise distance 
analysis confirming a larger distance between the MG ion and drug DTG for the G140S mutant 
system compared to the WT and R143. Further interaction analysis was performed to confirm 
the hypothesis that the S140 mutation could prevent drug binding by extracting structures at 
different snapshots of the simulation. Here, we found that the G140S mutation resulted in the 
drug being expelled from the binding pocket. We also observed weaker interactions for the Q92 




patients should first be screened for mutations and or novel variants to determine if the drug 
DTG will be efficacious or not. The model generated in this study can be used to tease out the 
effects of novel variants. A few limitations of this study are the use of RAL, EVG mutants and 
not considering novel RAL or DTG mutations. We also only simulated single mutations instead 
of double however we have yet to identify double mutants within the South African cohort of 
HIV-1C infected patients. Future work will include viral fitness assays to determine the effect 
of the mutant S140 on the HIV-1C virus and the effect of the drug DTG on the virus ability to 
persist in the presence of the drug.  
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Chapter 7 Mutations in Long Terminal Repeats Kb Transcription 
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7.4. Background 
HIV-1 subtype C (HIV-1C) is responsible for the majority of infections in sub-Saharan Africa. 
We selected 63 plasma-derived samples and generated Long Terminal Repeats (LTR) 
amplicons from people living with HIV (PLHIV) in South Africa to identify transcription factor 
binding sites. NF-κB plays an important role in regulating the viral gene expression from the 
viral promoter and controlling viral latency.  
7.5. Main findings 
LTR amplicons were sequenced and phylogenetically analysed. In our dataset, we identified F-
κB sites (n= 4; 6%) at position II and (n = 1; 1%) at position I among 63 sequences analysed. 
The majority of the sequences identified with H-κB at position II (n = 50; 79%) and position I 
(n = 55; 87%). Forty-nine (n = 49; 78%) sequences were found to exhibit C-κB site. 




identified all three NF-κB-binding sites in (n=44; 70%) the viral promoter–enhancer regions in 
South African patients. 
7.6. Study significance 
This study investigate the diversity in the regulatory motifs within the LTR which may 
influence viral fitness by acting at the level of transcription factor. This study also contribute to 
the knowledge diversity of difference in the regulatory motifs within HIV-1C LTR. 
7.7. Conclusion 
In summary, we report that South African HIV-1C contain C-κB- binding site in their LTR 
regions, but no evolution of fourth NF-κB as reported previously. Viral fitness may be 
influenced by differences in regulatory motifs by acting at the level of transcription level. 
Majority of our sequences have additional NF-κB sites signature for HIV-1C viruses; however, 
it remains to be established the potential effect of a third NF-κB site has on HIV-1C replicative 
capacity and rate of progression in people living with HIV-1C in South Africa. 
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Chapter 8 General discussion and future remarks 
8.1. Introduction 
8.2. Introduction 
The result chapters included in this thesis (two published manuscripts and two manuscripts 
under review) focused on the use of molecular techniques to analyse InSTIs in two cohorts 
(treatment-naïve and treatment-experienced patients). In the treatment-naïve cohort, we 
explored the structural impact of IN polymorphisms on the IN-reaction mechanism and InSTI 
susceptibility. In treatment-experienced patients, I focussed on the use of population-based 
Sanger sequencing and NGS to identify pre-existing mutations that could compromise InSTI 
rollout in PLHIV in South Africa. 
8.3. Resistance testing and HIV drug resistance  
RAMs against InSTIs and the efficacy of the use of DTG as a monotherapy have been 
established,117 which suggest the use of a NRTI backbone must be considered. Currently, in 
LMICs, due to high cost, GRT drug resistance testing is not widely accessible and incomplete 
viral load testing could possibly lead to functional DTG monotherapy resistance in different 
situations. In Southern Africa, where long delays in the management of viraemia have been 
documented, this could allow NRTI resistance to emerge in patients receiving DTG.118,119 
Furthermore, adults with pre-treatment RAMs (especially treatment-experienced patients) 
might have undetected NRTI mutations associated with reduced susceptibility to TDF and 
3TC.120 Several studies have identified a high prevalence of M184V in adults with virological 
failure receiving first-line NNRTI-regimens.23,27,121 This suggests that patients who switch from 
TDF, ETR and EFV to a combination of TDF, 3TC and DTG without prior confirmation of 
viral load suppression might be at increased risk of acquired HIVDR to DTG.122 Knowledge of 
the risks and benefits of this strategy should be considered as a possible high-priority research 
question as several cART programmes might not use viral load testing in transition to DTG-
based first-line cART. Although this transition could be justified by the advantages of DTG, 
programmes to accelerate viral load testing rollout should be supported, policy makers should 
be guided and HIVDR surveillance systems should be implemented across all public sectors.122  
8.4. Management of viraemia in patients 
In LMICs, the transition from EFV to a more efficacious InSTIs-based first-line cART is widely 
expected to increase levels of viral suppression. Challenges, such as inadequate retention in 




structures might reduce the effectiveness of this treatment regimen. Therefore, to measure the 
effectiveness of InSTIs in expanding viral load, coverage remains essential to identify patients 
who need urgent intervention because of viraemia. Furthermore, viraemia detection strategies 
for viral load monitoring should be reassessed for better management of patients who are failing 
treatment regimens.123 The development of RAMs in patients receiving DTG-based regimens 
has been rare in both low- and high-income countries.44,54 In some LMICs, resistance testing is 
not cost-effective and as a result is not widely used. If viraemia persists for more than three 
months regardless of adequate adherence, the WHO guidelines recommend switching to 
second-line cART. However, in LMICs these guidelines are not adequately implemented, 
leading to drug resistance, ongoing viraemia and morbidity.118,120 The introduction of first-line 
DTG could allow these guidelines to be simplified as poor adherence rather than HIVDR is 
likely to cause viraemia, which should greatly reduce the number of patients switching from 
first-line DTG to a second-line regimen. Management of viraemia should focus more on 
improving adherence than on treating HIVDR. 
8.5. Adherence interventions   
In LMICs, numerous adherence interventions have been explored, but evidence of an effect on 
virological suppression is weak. Accurate measurement of adherence is challenging.124 
Furthermore, adherence relies on a complex combination of behavioural, social medical and 
structural factors.125 For instance, HIVDR and not poor adherence, could cause a patient 
receiving NNRTIs-based first-line cART to have virological failure; however, a suppressed 
viral load could suggest good adherence. DTG as compared to EFV has a short half-life.126 A 
patient receiving DTG, who does not adhere to her/his treatment, could experience quicker viral 
rebound. Improved adherence should reflect in a rapid return to viral suppression. As the use 
of InSTIs is set to increase, viral load testing coverage should also be expanded in LMICs, 
which would make monitoring adherence and response to adherence interventions easier. This 
strategy might help to develop and implement evidence-based adherence interventions that 
would help to achieve early viral suppression.127 In South Africa, point-of-care viral load testing 
might be instrumental in helping to solve adherence challenges,  monitor the effect of 
counselling and to guide patients’ regimen diagnosis in differentiated care services.128 
8.6. Concerns and questions around DTG roll-out in low-to-middle-income countries  
The roll out of DTG as part of the first-line cART is arguably a significant step in HIV 
treatment evolution in LMICs. DTG has already been introduced in countries such as Tanzania, 




in LMICs, but specific questions remain unanswered. First, there are still safety concerns for 
pregnant women receiving DTG and/or women in childbearing age with adverse birth outcomes 
128. According to the WHO, in the recently concluded International AIDS conference showed 
additional data from two clinical trials in Africa  that compared the safety of DTG and EFV. 
The risk of neural tube defects are significantly lower than what was previously reported (IAS, 
2019). Second, how will adherence support interventions be integrated with viral load 
monitoring to maximise virological re-suppression and effectively monitor patients 
with viraemia on DTG. Third, how will pre-treatment or acquired mutations that confer 
resistance to NRTIs affect the efficacy of DTG-based regimen either in first and/or second-line 
regimen? Fourth, will the replacement of first-line or second-line regimens or both with DTG 
be cost-effective? Will the roll out of DTG affect the cost-effectiveness of HIV drug resistance 
testing and viral load monitoring? Finally, without proper adherence, viral load monitoring 
and/or drug resistance testing, there will be high chance of evolution of DTG RAMs as observed 
in high-income countries. There is clear benefit of DTG when there is proper clinical 
management with optimal adherence, viral load monitoring and resistance testing. Data is 
lacking about the clinical evolution of DTG resistance in public health setting for this massive 
roll-out of DTG. Improper management of DTG could jeopardize the future use of newer 
InSTIs like CAB or BTG in the settings. These gaps should be addressed as part of DTG roll-
out particularly regarding safety surrounding pregnant women and women of childbearing age 
and HIV drug resistance surveillance would assist health systems and clinicians to maximise 
the promising benefits of InSTIs regimens 128.  
8.7. Conclusion 
The study addressed the existing knowledge gaps in the prevalence of InSTI drug resistance in 
South African treatment-naïve patients. The study also shows treatment-experienced patients 
suspected of failing a first- and/or second-line treatment regimen. The data generated from this 
study represent baseline findings regarding InSTI RAMs for both treatment-naïve and 
treatment-experienced patients in a South African context. These findings are important to 
verify whether the new InSTI regimens can ensure a supressed viral load and good treatment 
outcome for PLHIV in South Africa.  
Below are the main conclusions: 
• The introduction of the InSTIs class of cART regimen into the national treatment 
programme could potential help in the management of the HIV epidemic in South 




monitored closely for maximum efficiency to ensure that patients receive the best 
treatment. The possible emergence of RAMs as well as subtype-specific resistance to 
this class of cART regimen cannot be ignored. 
• The pattern of RAMs identified was against PIs, NRTIs and NNRTIs from patients on 
the South African second-line national cART programme. Observed InSTI mutation 
levels were low. Major mutations, such as T66I and Y143R were identified at 1% each, 
and accessory mutations, such as E157Q and T97A were identified at 2% and 1% 
respectively. Due to the high public health burden, I strongly recommend continued 
viral load monitoring in South Africa. This will not only detect treatment failure earlier 
but will also detect poor treatment adherence.  
• We presented extensive analyses of IN polymorphisms in the IN-reaction mechanism 
and InSTI susceptibility. These analyses suggest that naturally occurring 
polymorphisms may affect the structural stabilities of the IN gene, viral DNA binding 
and drug propensity. The data generated from this study provide guidance for 
investigating how polymorphism can affect treatment response. 
• In this study, I used HTS to quantify the DRM in both minor (< 20% of the population) 
and major (> 20% of the population) viral quasi-species and identified increased PI 
RAM in minor viral populations. This study shows that the use of high-throughput 
resistance testing for GRT can greatly improve the identification of PI RAMs in bPI-
failing patients. Using HTS-GRT, PI RAMs (V82A) and RTI RAMs (K65R, M184V or 
K103N) were identified in < 20% of the population that Sanger sequencing failed to 
identify, strengthening their role in detecting the acquired mutations early. 
 
In this study, we observed two NF-kB sites from 18/63 (29%) LTR sequences analyzed. Studies 
have shown that deletions of either one or two NF-kB sites from the enhancer region can lead 
to substantially decreased replication levels and that the virus becomes less infective. We report 
that South African HIV-1C contain C-kB-binding site in their LTR regions, but no evolution of 
fourth NF-kB. Viral fitness may be influenced by differences in regulatory motifs by acting at 
the transcription level. Majority of our sequences have additional NF-kB sites signature for 
HIV-1C viruses; however, the potential effect of a third NF-kB site has on HIV-1C replicative 






Baseline resistance testing and quantification of drug-resistant viral populations before the 
initiation of cART reduce the probability of developing virological treatment failure. In 
countries such as South Africa, baseline resistance testing is expensive as compared to high-
income countries. In addition to the, South Africa guidelines recommend baseline resistance 
testing to patients for the following reasons: pre-exposure prophylaxis in the last six months, 
sexual exposure to a person with known drug-resistant HIV and patients who are known to have 
failed cART regimens. In South Africa, population-based Sanger sequencing has been used as 
genotype testing tool when a patient has met any of the required recommendations. We also 
propose the use of HTS. 
8.8. Overall strength and limitations of the work 
There are several strengths and limitations to this work. Samples were stored since 2001, as 
they were obtained between 2000 and 2001 (Paper I). These samples are unique because they 
were obtained before cART roll-out in South Africa. Despite this advantage, our study was 
limited to the number of samples that were analysed. No viral load data is available and CD4+ 
T cell analysis was not performed on these samples. This is the first study to look at the 
prevalence of InSTIs in patients receiving LPV/r and ATV as their bPIs from South Africa, this 
manuscript therefore contributed to expanding current HIV-1 knowledge regarding LPV/r and 
ATV resistance. The majority of our patients were receiving LPV/r as their bPIs compared to 
ATV. We cannot tell whether the patients having RAL resistance, according to the sequences, 
have had access to a RAL-based treatment regimens. No adherence data was available for these 
patients. This manuscript provided the first glimpse of nucleoprotein organisation in viral 
sequences obtained from South African treatment-naïve patients and different subtypes. Data 
generated from this manuscript could be used to deduce the effect of a polymorphism in the IN 
of different HIV-1 subtypes. The limitation for this manuscript is the DNA used in this structure 
determination contains a T–T mismatch in the double-stranded region (Paper IV). This 
mismatch may have affected DNA bending, which in turn would have affected spatial 
oligomerization of IN molecules in the intasome.  
This study also shows the use of HTS resistance testing for GRT can greatly improve the 
identification of PI RAMs in bPI failing patients. Using HTS-GRT, PI RAMs (V82A) and RTI 
RAMs (K65R, M184V or K103N) were identified in <20% population that sanger-based 
sequencing failed to identify strengthening their role in detecting the acquired mutations early 
(Paper II and IV).  In Chapter 2, there were no major mutations against InSTIs detected (prior 




– 2018), and 5/56 (8.9%) patients harboured 3 virus with high level resistance to InSTIs as 
detected by NGS (Chapter 4; 2017 – 2018). This is an evolving epidemic, it would be critical 
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Supplementary Table 1: Demographical and clinical data of patients 
Isolate Race / 
Gender 
Orientation Symptoms Subtype (IN 
gene) 
TV0116 CF Hetero Asymptomatic C 
TV0118 CF Hetero Asymptomatic C 
TV0122 CM MTCT Asymptomatic B 
TV0124 BF Hetero Shingles, Miositis C 
TV0126 BM Hetero Asymstomatic C 
TV0127 BM Hetero symp to stage II C 
TV0128 BF Hetero TB C 
TV0132 BF Hetero Weight loss, Oral candidiasis, 
Pneumonia 
C 
TV0133 BM Hetero TB C 
TV0135 CF Hetero Asymstomatic C 
TV0137 BF Hetero DVT, Ca CervixIIIB, prev 
Radiotherapy 
C 
TV0139 BF Hetero Asymstomatic C 
TV0141 BM Hetero Asymstomatic C 
TV0142 BF Hetero Asymstomatic 
 
TV0143 BM Hetero TB treatment completed C 
TV0144 BF Hetero Asymstomatic C 
TV0145 BF Hetero STD C 
TV0147 BF Hetero Asymstomatic C 
TV0148 BM Hetero Current pleural effusion C 
TV0149 CF MTCT Pneumonia x2 C 
TV0152 BM Hetero Asymptomatic C 
TV0153 BM Hetero Asymptomatic B 
TV0155 BM Hetero Asymptomatic C 
TV0157 BM Hetero TB C 















Isolate Race / 
Gender 
Orientation Symptoms Subtype (IN 
gene) 
TV0168 CF Hetero Candida C 
TV0173 BM Hetero Symptomatic of TB C 
TV0175 CF Hetero Seborrhea C 
TV0177 BF Hetero Anal Warts C 
TV0180 BF MTCT Septicemia, PID, Lymphoma,  C 
TV0181 BF Hetero Asymptomatic C 
TV0182 BF Hetero Asymptomatic C 
TV0183 BF Hetero Asymptomatic C 



















TV0345 BF Hetero Asymptomatic C 
TV0346 BF Hetero Asymptomatic C 
TV0347 CF Hetero Asymptomatic C 
TV0348 BM Hetero Oral thrush, Prurigo, Weight Loss, 
Diarrhoea 
C 
TV0349 BM Hetero Asymptomatic C 
TV0350 BM Hetero Weight Loss, Oral thrush C 
TV0353 CF Hetero 
 
C 
TV0356 CF Hetero Asymptomatic B 
TV0364 BF Hetero Focal neurologic deficits C 
TV0365 CM Hetero Opthamic Zoster, Candidiasis, 
Severe Psoriases 
C 
TV0366 CF Hetero Thrombocytopenia C 
TV0367 CF Hetero Asymptomatic C 
TV0370 BM Hetero Asymptomatic C 
TV0371 BF Hetero Asymptomatic C 
TV0372 BF Hetero TB C 






Isolate Race / 
Gender 
Orientation Symptoms Subtype (IN 
gene) 
TV0375 BF Hetero TB<1year, Genital Warts, 
Candidiasis 
C 
TV0376 BF Hetero Asymptomatic C 




TV0398 BM Hetero 
 
C 
TV0404 CF Hetero Asymptomatic B 
TV0405 BF Hetero Asymptomatic C 
TV0406 BF Hetero 
 
C 
TV0407 BF Hetero Prurigo, Lymphadenopathy C 
TV0412 BM Hetero Chronic staph. Aur. skin sepsis A 
TV0413 CF Hetero Asymptomatic C 
TV0417 CF Hetero 
 
C 






TV0424 BM MTCT PTB C 
TV0425 BF Hetero Asymptomatic C 
TV0426 BF Hetero Prurigo C 
TV0427 BF Hetero Asymptomatic C 




TV0433 CF Hetero Asymptomatic C 
TV0434 BF Hetero TB C 
TV0435 BF Hetero Asymptomatic C 
TV0436 BM Hetero Asymptomatic C 
TV0437 BM Hetero Asymptomatic C 
TV0438 BM Hetero TB C 
TV0442 WF Hetero 
 
C 
TV0445 Mix Hetero Asymptomatic C 
TV0446 CF Hetero Asymptomatic C 




BF: Black Female, BM: Black Male, CF: Coloured Female, CM: Coloured Male, WF: White 
Female, WM: White Male, PTB: Pulmonary Tuberculosis, DVT: Deep Vein Thrombosis: 
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